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ABSTRACT 
Cholera, an acute and severe dehydrating diarrheal disease caused by Vibrio cholerae O1 
remains a major public health concern which has significant morbidity and mortality 
worldwide. Several efforts have been made to develop cholera vaccines that could confer 
long term protection. T cells play an important role in immunity to cholera and may 
contribute to the activation of B cells. So, understanding the memory T cell responses is 
important for optimizing design of oral cholera vaccine or immunization strategies. It had 
been investigated that immunization with the oral cholera vaccine, Shanchol, induces V. 
cholerae antigens specific CD4+ and CD8+ memory T cell responses in Bangladeshi 
adult participants. The study enrolled 45 adult healthy participants and divided them into 
three groups (In each group n=15) where two groups received double doses of the 
vaccine (14 days and 30 days apart) and another group received single dose of the 
vaccine alone. The main objective of the study was to examine V. cholerae antigens, 
including membrane preparation (MP) and mutant CT (mCT) specific T cell responses by 
the flow cytometric assay of the specific cell-mediated immune responses in activated 
whole blood (FASCIA). After vaccination stimulation with MP showed better 
proliferative CD4+/CD45RO+ and CD8+/CD45RO+ memory T-cell responses than mCT 
at day 7 compared to baseline in all vaccine cohorts. However, one month after the last 
dose of the vaccine, the responses were all most diminished over the period of day 90 in 
all vaccination regimens. Overall a high baseline proliferative CD4+ and CD8+ T cell 
responses to mCT was found in all vaccinee groups but it did not show increased memory 
T cell responsiveness significantly to mCT after vaccination. This is because the absence 
of cholera toxin (CT) and presence of Lipopolysaccharide (LPS) of different V. cholerae 
strains in the vaccine. Again, V. cholerae O1 Ogawa and Inaba specific vibriocidal 
antibody responses were also observed maximum at day 7 after administration of one 
dose of vaccine in all vaccine cohorts. After one month of last dose of the vaccination, 
the responses started to wane gradually and became vastly reduced at subsequent study 
days in all vaccination regimens. In contrast the two doses given 30 days apart showed 
significantly increased responses in comparison to baseline over the period of day 90. 
These findings suggested that single dose vaccine regimen was as effective as double 
dose vaccine regimens. So it can be concluded that this early proliferative T cell response 
is a potent tool that provides help for the generation of subsequent memory B cell 
responses. However, additional studies are needed to determine whether these early T-
cell-mediated events would help to design a more effective vaccine as well as provide 
long-lasting immunity.  
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1.1. Cholera- the oldest epidemic prone disease 
Cholera, a severe diarrheal disease,  has been well known from the nineteenth century 
and still remains the most feared and stigmatized disease, particularly in the developing 
countries of Asia, Africa, and recently, the Caribbean islands. It is an acute intestinal 
infection characterized by profuse watery diarrhea; vomiting and rapid dehydration. 
Cholera is one of the oldest and best understood of the epidemic prone diseases (John D. 
Clemens 2014). It is endemic in more than 50 countries causing 3 to 5 million cases of 
secretory diarrhea and over 100,000 deaths annually (Zuckerman, Rombo et al. 2007) 
(WHO 2010).  
Vibrio cholerae is the causative microorganism of this disease and human body is the 
only known natural host of this organism. The disease is spread mainly by fecal-oral 
contamination of water and food. But direct transmission from person to person is not 
uncommon (Nelson EJ 2011) (Weil, Khan et al. 2009). 
Though naturally acquired infection has been shown to protect against subsequent 
symptomatic disease for 3 to 8 years (Koelle, Rodo et al. 2005) (Levine, Black et al. 
1981), currently available oral killed cholera vaccines (OCVs) provide protection for 6 
to 36 months, depending on which OCV is studied and the age of the recipient (Sinclair, 
Abba et al. 2011) (Sur D 2011 ) (WHO 2010).  
It has been shown that the systemic and mucosal memory play an important role in 
protective immunity induced by vaccines (Sallusto, Lanzavecchia et al. 2010) and T 
cells play an important role in immunity to cholera (Kuchta, Rahman et al. 2011) 
(Harris, Bhuiyan et al. 2009) (Weil, Khan et al. 2009) (Bhuiyan, Lundin et al. 2009). 
Therefore, understanding the relationship between the developments of memory T cells 
response could be critical to optimizing oral cholera vaccine design or immunization 
strategies. 
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1.2. Vibrio cholerae- The etiologic agent of cholera 
1.2.1. General Characteristics: Vibrio cholerae is a curved, Gram-negative rod, 
facultative anaerobic, comma-shaped bacterium belong to the family vibrionaceae and 
genus Vibrio. It comprises of a microscopic size around 1 μm in width and 2-3 μm in 
length and motile by at least one polar flagellum (Baumann 1984). Vibrios display a 
wide variation in colony morphology and color  (Stoll 1982). 
 
 
Figure 1.1: Vibrio cholerae (http://www.futura.sciences.com) 
Although V. cholerae can grow in water of lower salinity, these organisms grow best in 
the presence of salt and  warmer weather  (Colwell 1996).  
 
1.2.2. Genomic Structure: 
V. cholerae have two circular chromosomes, together with 4 million base 
pairs of DNA sequence and 3,885 predicted genes (Heidelberg, Eisen et al. 2000). The 
genes for cholera toxin are carried by CTXphi (CTXφ), 
a temperate bacteriophage inserted into the V. cholerae genome. CTXφ can transmit 
cholera toxin genes from one V. cholerae strain to another through horizontal gene 
transfer. The genes for toxin coregulated pilus are coded by the VPI pathogenicity 
island (VPIφ) (Control 2013). V. cholerae contains a genomic island of pathogenicity 
and is lysogenized with phage DNA. Therefore the genes of a virus were integrated into 
the bacterial genome which made the bacteria pathogenic (Control 2013). 
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Figure 1.2: Genomic Structure of V. cholerae. The expression of the primary V. 
cholerae virulence factors, toxin-coregulated pilus and cholera toxin, occurs via a transcriptional 
cascade involving several activator proteins and serves as a paradigm for the regulation of 
bacterial virulence (Control, C. f. D. 2013). 
 
1.2.3. Classification 
V. cholerae is classified into more than 200 serogroups based on the O antigen of the 
lipopolysaccharide (LPS) antigen (Morris 2003). Among these, only O1 and O139 
serogroups cause epidemic cholera. Vibrio cholerae O1 is further classified into two 
biotypes, classical and El Tor (Sack, Sack et al. 2004). Two major serotypes exist, 
Ogawa and Inaba, which vary in prevalence with time  (Longini, Nizam et al. 2007).  
 
Strains of the Ogawa serotype express the A and B antigens and a small amount of C 
antigen, whereas Inaba strains express only the A and C antigens. A third serotype 
(Hikojima) expresses all three antigens but it is rare and unstable (Sack, Sack et al. 
2004). The O1 El Tor biotype predominates in most current infections. These two 
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serogroups- O1 and O139 are pathogenic due to their production of an enterotoxin, 
cholera toxin (CT) that promotes the secretion of fluids and electrolytes into the 
intestinal lumen, resulting in diarrhea. The sixth pandemic and presumably the fifth were 
caused by V. cholerae O1 of the classical biotype (Pazzani, Scrascia et al. 2006), but the 
seventh pandemic was due to the El Tor, which started in 1961 and even continues today 
(WHO 2010). 
 
 
Figure 1.3: The current classification scheme of epidemic and non-epidemic strains 
of V. cholerae 
 
V. cholerae O1 and O139 cause clinical disease by producing Cholera toxin (CT) that 
promotes the secretion of fluid and electrolytes into the lumen of the small intestine. 
 
1.3. Virulence factors 
1.3.1. Cholera toxin – an enterotoxin 
The cholera toxin is an oligomeric complex made up of six protein subunits: a single 
copy of the A subunit (part A, enzymatic), and five copies of the B subunit (part B, 
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receptor binding), denoted as AB5. A1 and A2 are connected by a single disulfide bond 
(Zhang, Scott et al. 1995). The B subunits are responsible for binding to a ganglioside 
(monosialosylganglioside, GM1) receptor located on the surface of the cells that line the 
intestinal mucosa (Shamini, Ravichandran et al.). 
 
Figure 1.4: 3D structure of Cholera toxin 
(http://www.rcsb.org/pdb/explore/explore.do?structureId=1xtc) 
 
Although being synthesized as a single polypeptide chain, CTA is post-translationally 
modified through the action of a V. cholerae protease that generates two fragments, 
CTA1 and CTA2, which however still remain linked by a disulphide bond. The toxic 
(enzymatic ADP-ribosylating) activity of CTA resides in CTA1, whereas CTA2 serves 
to insert CTA into the CTB pentamer. The CTB pentamer is held together by 
approximately 130 hydrogen bonds and 20 salt bridges which render stability of 
pentameric CTB to proteases, bile components and other factors in the intestinal milieu. 
It has been suggested that pentamer-pentamer interactions may possibly further add to 
the stability (Sanchez and Holmgren 2011). 
 
1.3.2. Lipopolysaccharide (LPS) - an endotoxin 
All Gram-negative bacteria express a glycolipid component called endotoxin, 
lipopolysaccharide (LPS), which participate in the physiological functions of the 
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bacterial outer membrane. The LPS is composed of lipid region, core region and 
variable polysaccharide region (Fig-1.5). Toxicity is associated with the lipid component 
(Lipid A) and immunogenicity is associated with the polysaccharide components and 
both act as determinants of virulence. Polysaccharide attached to core region (O side 
chain) consists of repeating oligosaccharide subunits made up of 3 - 5 sugars unit and 
vary up to 40 repeat units. V. cholerae O1 differs from other V. cholerae O serogroups 
by O side chain orientation. O antigen and capsule play important role for intestinal 
colonization (Chiang and Mekalanos 1999) (Nesper, Lauriano et al. 2001) (Waldor, 
Colwell et al. 1994) (Iredell, Stroeher et al. 1998) (Angelichio, Spector et al. 1999) 
(Attridge, Fazeli et al. 2001). LPS core oligosaccharide (core-OS) also has such role 
(Herrington 1988) (Lee 1999).  
 
 
 
 
Figure 1.5: Lipopolysaccharide of gram negative bacteria: LPS consists of O side chain, core 
polysaccharide and lipid Aregion (http://origin-ars.els-cdn.com/content/image/1-s2.0-
S128645790201612X-fx1.jpg) 
 
In addition to causing endotoxic shock, LPS is pyrogenic, can activate macrophages and 
complement, and is mitogenic for B lymphocytes that induce interferon production. It 
also causes tissue necrosis and tumor regression and has adjuvant properties. The 
endotoxic properties of LPS reside largely in the lipid A components (Finkelstein 1962). 
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1.4. Pathogenesis of Cholera 
Although the cholera toxin (CT) is directly responsible for the manifestation of diarrhea, 
cholera pathogenesis associated with a number of factors acting synergistically to 
promote virulence. The pilus colonization factor, toxin-coregulated pilus (TCP) mediate 
colonization of brush borders of epithelial cell of the small intestine (Faruque, Nair et al. 
2004). Colonization is a prerequisite to establish a productive infection by V. cholerae. 
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Figure 1.6: Mode of action of cholera toxin 
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After successful colonization, V. cholerae secrete a potent enterotoxin (CT). This 
enterotoxin is an 87-KD protein, consisting of five B subunits (103 amino acid residues 
in each) and one A subunit (240 amino acid residues in which the B subunits form a 
pentagonal ring surrounding the A subunit  (Kenneth Todar 2012). 
The toxin starts to exert its effect by irreversibly binding to its cell surface receptor 
monosialosylganglioside (GM1 ganglioside) present on the surface of intestinal mucosal 
cells (Kovach 1996 ). CT is taken into the cell, possibly via receptor mediated 
endocytosis. This process is accompanied by cholera toxin activation through the 
proteolytic cleavage and disulfide bond reduction of the A subunit to two fragments, A1 
(~195 residues) and A2 (~ 45 residues) where upon A1 is released into the cytosol 
(Kaper 1994). Once inside the cell, A1 catalyzes the transfer of the ADP-ribose unit 
from NAD
+
 to an Arginine side chain of Gsα, ADP ribosylated GsαGTP can activate 
adenylate cycalse but is incapable of hydrolyzing its bound GTP. As a consequence, 
Cholera toxin activated adenylate cyclase remains “locked” in its active state (Kaper 
1994). This leads to uncontrolled production of intracellular cAMP (Fig 1.6). 
Elevated cAMP level in turn activates protein kinase A, which opens the luminal cystic 
fibrosis transmembrane conductance regulator (CFTR) Cl¯ channel and inhibits the 
Na
+
/H
+
 exchanger by protein phosphorylation. Thus increase secretion of H20, Na
+
, K
+
, 
Cl
-
, and HCO3
-
 into the lumen of the small intestine. The net result is voluminous, life 
threatening intestinal electrolyte and fluid secretion in cholera patient. 
1.5. Epidemiology 
Cholera occurs in both endemic and epidemic patterns. In the past decade, devastating 
epidemics of cholera occurred in Angola, Ethiopia, Zimbabwe, Pakistan, Somalia, 
Sudan, Vietnam, and Haiti. Among immunologically naive populations, cholera affects 
all age groups, and epidemics can be associated with high case-fatality rates (Harris 
2008). In Asia, cholera occurs seasonally before and after the monsoon rains (Sack, Sack 
et al. 2004). The incidence is highest in children, and the disease can occur in neonates 
(Deen, von Seidlein et al. 2008) (Khan, Hossain et al. 2009). This pattern was recorded 
in Haiti, where cholera had been notably absent before 2010 (Harris 2012). The first 
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cholera pandemic occurred in the Bengal region of India starting in 1817 through 1824. 
The disease dispersed from India to Southeast Asia, China, Japan, the Middle East, and 
southern Russia. The second pandemic lasted from 1827 to 1835 and affected the United 
States and Europe particularly due to the result of advancements in transportation and 
global trade, and increased human migration, including soldiers (Harris 2012). 
 
 
Figure 1.7: Major cholera outbreaks after 2000 (Harris 2012) 
The third pandemic erupted in 1839, persisted until 1856, extended to North Africa, and 
reached South America, for the first time specifically infringing upon Brazil. Cholera hit 
the sub-Saharan African region during the fourth pandemic from 1863 to 1875. 
The fifth and sixth pandemics ranged from 1881–1896 and 1899-1923.  
The final seventh pandemic originated in 1961 in Indonesia and is marked by the 
emergence of a new strain, nicknamed El Tor, which still persists today in developing 
countries (Bishop 2011) (Harris 2012). 
Late in October 2010, a cholera outbreak was reported in Haiti (Times 2010). A recent 
study concluded that the Haitian cholera epidemic was most likely a result of an 
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introduction of a strain from a distant geographic location and derived from human 
activity. The examined genomic diversity of Haitian isolates was presented an effort to 
contribute to the understanding of the origin.  
 
1.6. Clinical manifestations of cholera 
1.2.1. Infectious Dose 
The infectious dose of V. cholerae O1 has been estimated to be 10
5
 −108 CFU in human 
volunteers, but may be as low as 10
3 
CFU in the presence of achlorhydria (Nelson, 
Harris et al. 2009). 
 
1.2.2. Incubation Period 
The incubation period ranges between 12 hours to 5 days (Nelson, Harris et al. 2009) 
 
1.2.3. Signs and Symptoms 
Onset of cholera is sudden with profuse, watery diarrhea with or without symptoms such 
as anorexia and abdominal discomfort (Sack, Sack et al. 2004). The stool color becomes 
pale gray with an inoffensive, slightly fishy odor. Mucus in the stool imparts the 
characteristic rice water appearance (Sack, Sack et al. 2004). Vomiting is often present, 
occurring a few hours after the onset of diarrhea (Clemens, Sack et al. 1986). Muscle 
cramps may occur as water and electrolytes are lost from body tissues. Loss of skin 
turgor, scaphoid abdomen, and weak pulse are characteristic of cholera. The initial stool 
may exceed 1 L, and several liters of fluid may be secreted within hours, leading to 
hypovolemic shock (Finkelstein 1996). 
1.7. Prevention and diseases management  
The treatment for cholera recommended by WHO is oral rehydration solution (ORS), 
which reduces mortality from 50% down to 1%. In severe cases intravenous fluid 
replacement is necessary. Antibiotics can be used to treat severe cholera and may 
shorten the duration of disease and thereby decrease the risk for further spread of the 
disease. Mass administration of antibiotics is not recommended, as it has no effect on the 
spread of cholera and contributes to increasing antimicrobial resistance (WHO 2012) 
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(WHO 2009). The best way to avoid cholera is to have access to safe water supplies, and 
avoid contaminated foods. However, safe water supplies are not available to a great 
proportion of the world population. Therefore, an effective cholera vaccine is an urgent 
need to prevent illness and deaths of thousands of people around the world and this is 
why the effectiveness of Shanchol vaccine is investigated in this study. 
1.8. The Immune System 
The immune system is an interactive network of lymphoid organs, cells, humoral 
factors, and cytokines.  The  essential  function  of  the  immune  system  in host  
defense  is  best  illustrated  when  it  goes  wrong;  under activity  resulting  in  the  
severe  infections  and  tumors  of immunodeficiency,  over activity  in  allergic  and  
autoimmune  disease. The immune system responds in a specific way to pathogens and 
displays a long-term memory of earlier contacts with the disease agents (Parkin and 
Cohen 2001). 
1.8.1. Innate & Adaptive Immune System 
Immunity is divided into two “lines of defense” determined by the speed and specificity 
of the reaction.  The first, representing a non-specific (no memory) response to antigen 
(substance to which the body regards as foreign or potentially harmful) known as the 
innate immune system; and the second, the adaptive immune system, which displays a 
high degree of memory and specificity (Parkin and Cohen 2001).  
The innate immune system represents the first line of defense to an intruding pathogen. 
The innate immunity  is  sometimes  used  to  include  physical, chemical, and 
microbiological barriers, but more usually encompasses  the  elements  of  the  immune  
system (neutrophils,  monocytes,  macrophages,  complement, cytokines,  and  acute  
phase  proteins)  which  provide immediate host defense. The highly conserved nature of 
the response, which is seen in even the simplest animals, confirms its importance in 
survival (Parkin et al.  2001) . 
Adaptive immunity is the hallmark of the immune system of higher animals. This 
response consists of antigen-specific reactions through T lymphoctyes and B 
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lymphocytes. Whereas the innate response is rapid but sometimes damages normal 
tissues through lack of specificity, the adaptive response is precise, but takes several 
days or weeks to develop. The adaptive immune response has memory, so that 
subsequent exposure leads to a more vigorous and rapid response, but this is not 
immediate {Parkin, 2001 #31} 
 
Figure 1.8: Innate and adaptive immunity (Dranoff 2004) 
1.8.2. Types of adaptive immune responses  
There are two types of adaptive immune responses (Abul K. Abbas 2007): 
a) Humoral immunity or Antibody-mediated immunity (AMI) 
b) Cell-mediated immunity 
 
Antibody-mediated immunity (AMI) is the type of adaptive immunity that is mediated 
by soluble host proteins called antibodies or immunoglobulins. It is largely due to the 
presence of circulating antibody molecules in the serum and is also called circulating 
immunity or humoral immunity. If a naive (unstimulated) B cell encounters an antigen, 
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it is stimulated to develop into a plasma cell which produces the antibodies that will 
react with the stimulating antigen. They also develop into clones of identical reactive B-
cells called memory B-cells (Kenneth Todar 2012). 
 
 
Cell-mediated immunity (CMI) is the type of adaptive immunity that is mediated by 
specific subpopulations of T-lymphocytes called effector T-cells. In non immune 
animals precursor T-cells (pT cells) exist as "resting T cells". They bear receptors for 
specific antigens. Stimulation with antigens results in their activation.  
 
After that, the cells enlarge, enter into a mitotic cycle, reproduce and develop into 
effectors T-cells whose activities are responsible for this type of immunity. They also 
develop into clones of identical reactive T-cells called memory T-cells  (Kenneth Todar 
2012). 
 
 
 
Figure 1.9: Types of adaptive immunity (Abbas 2010) 
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Both activated T helper (TH) cells and cytotoxic T lymphocytes (CTLs) serve as 
effectors cells in cell-mediated immune reactions. Cytokines secreted by TH cells can 
activate various phagocytic cells, enabling them to phagocytose and kill microorganisms 
more effectively. CTLs participate in cell-mediated immune reactions by killing altered 
self-cells; they play an important role in the killing of virus infected cells and tumor 
cells (Richard A. Goldsby 2006).  
 
1.8.3. Cellular components of the Immune System 
The immune system has developed to protect the host from pathogens and other foreign 
substances. The immune system consists of many cells that take part in the response 
against pathogen  (Male 2006). 
1.8.3.1. B-cell 
About 5-15% of the circulating lymphoid pool is B cells, which are defined by the 
presence of the surface immunoglobulin. These immunoglobulins function as membrane 
bound antigen receptors on B cell and soluble circulating antibodies (Roitt Ivan 2001). 
Depending on the structure of the heavy chain, immunoglobulins have multiple classes 
and sub-classes: IgG (G1-G4) - 76%, IgM-8%, IgA (A1, A2)-15%, IgD-1%, IgE-
0.002%. B-cells perform two important functions; they differentiate into plasma cells 
and produce antibodies, and they serve as APCs. When TH cells sensitizes or primes the 
naive B cell, it undergoes clonal selection, which means the antigen specific surface Ig 
(sIg) containing B-cell is selected and activated to expand into a clone of cells with the 
same antigen specificity. Most of the family of clones becomes plasma cells. These 
cells, after an initial lag, produce highly specific antibodies at a rate of as many as 2000 
molecules per second for four to five days. The other B cells become long-lived memory 
cells (Finkelstein 1962). 
1.8.3.2. T Cells  
 
T-lymphocytes belong to a group of white blood cells (WBC) known as lymphocytes are 
defined by expressing the T cell receptor (TCR), a complex of trans-membrane proteins 
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able to recognize a peptide excised from a protein-antigen, if this peptide is presented on 
MHC.  They are called T cells because they mature in the thymus (although some also 
mature in the tonsils) (Alberts B 2002) (Ward 2014). 
There are two major types of T cells, Helper T cells (CD4
+
) and cytotoxic T cells 
(CD8+). CD4+ T cells account for 45% (900/µL) of lymphocytes while CD8+ T cells 
account for 30% (600/µL). There are several subsets of T cells, each with a distinct 
function. 
 
1.8.3.2.1. Subsets of T-Cells 
 Helper T Cells (TH) 
As this population of T cell expresses CD4 glycoprotein on their surface, these cells 
named as CD4+ T cells. They recognize antigens when presented along with Class II 
MHC molecules. T helper cells (TH cells) assist other white blood cells in 
immunologic processes, including maturation of B cells into plasma cells and memory 
B cells, and activation of cytotoxic T cells, inflammatory leukocytes and macrophages 
and secretes cytokines (Gutcher and Becher 2007). These cells can differentiate into 
one of several subtypes, including  TH1, TH2, TH3, TH17, Th9, or TFH, which secrete 
different cytokines to facilitate a different types of immune responses (Gutcher and 
Becher 2007). 
Types of Helper T Cells 
TH1: These cells participate in cell-mediated immunity. They are essential for 
controlling such intracellular pathogens such as viruses and certain bacteria. TH1 cells 
help B cells to produce antibody and they activate macrophages by secreting interferon γ 
(IFNγ). They provide cytokine-mediated "help" to cytotoxic T cells possibly the body's 
most potent weapon against intracellular pathogens (Abbas 2010). 
TH2: TH2 cells produce IL-4, IL-5, IL-6, IL-10 and IL-13. These provide help for B cells 
and are essential for the production of IgE antibodies and perhaps assist in the production 
of other classes as well (Abbas 2010). 
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TH17: TH17 cells are named for the cytokine IL-17 they produce. These protect surfaces 
(skin, lining of the intestine) against extracellular bacteria. They seem to enhance 
neutrophil action early in an adaptive immune response. Effector TH17 cells leave the 
lymph node and migrate to the site of infection. There, they re-encounter their antigenic 
peptides presented on macrophage MHC II and respond with secretion of IL-17 and IL-
22. Most cells express IL-17 receptors (Abbas 2010). 
 
 Follicular Helper T cell 
These cells provide help to B cells enabling them to develop into antibody-
secreting plasma cells. This occurs in nests of lymphoid cells called follicles in 
the lymph nodes.  
 
 Cytotoxic T Cells (TC) 
Cytotoxic T cells (TC cells or CTLs) destroy virally infected cells and tumor cells, and 
are also implicated in transplant rejection. These cells are also known as CD8
+
 T cells 
since they express the CD8 glycoprotein at their surface. These cells recognize their 
targets by binding to antigen associated with MHC class I molecules, which are present 
on the surface of all nucleated cells. Through IL-10, adenosine and other molecules 
secreted by regulatory T cells, the CD8
+
 cells can be inactivated to an anergic state, 
which prevents autoimmune diseases (Willinger, Freeman et al. 2005).  
 
 Memory T cells 
Memory T cells are a subset of antigen-specific T cells that persist long-term after an 
infection has resolved. They quickly expand to large numbers of effector T cells upon 
re-exposure to their cognate antigen, thus providing the immune system with "memory" 
against past infections. Memory T cells comprise three subtypes: central memory T cells 
(TCM cells) and two types of effector memory T cells (TEM cells) and effector memory 
RA (TEMRA cells) (Willinger, Freeman et al. 2005).   
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Memory cells may be either CD4
+
 or CD8
+
. They typically express the cell surface 
protein CD45RO (Akbar, Terry et al. 1988). Long-term immunological protection 
depends on both the quantity and quality of the memory T cells that are formed. Vaccine 
boosters most probably enhance immunological protection by affecting the quality and 
quantity of memory T cells. Therefore, memory T cell is used as a parameter to evaluate 
Shanchol vaccine in this study. 
Figure 1.10: The different ways of memory CD4+ T-cells by which it can protect the host 
(MacLeod 2009) 
 
 Regulatory T cells 
Regulatory T cells (Treg cells), formerly known as suppressor T cells, are crucial for the 
maintenance of immunological tolerance. Their major role is to shut down T cell-
mediated immunity toward the end of an immune reaction and to suppress auto-reactive 
T cells that escaped the process of negative selection in the thymus. Two major classes 
of CD4
+
 Treg cells are naturally occurring Treg cells and Adaptive Treg cells. 
 Natural killer T cells 
Natural killer T cells bridge the adaptive immune system with the innate immune 
system. Unlike conventional T cells that recognize peptide antigens presented by major 
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histocompatibility complex (MHC) molecules, NKT cells recognize glycolipid antigen 
presented by a molecule called CD1d. Once activated, these cells can perform functions 
ascribed to both TH and TC cells (i.e., cytokine production and release of cytolytic/cell 
killing molecules). They are also able to recognize and eliminate some tumor cells 
(Terabe and Berzofsky 2008). 
 
1.8.4. The Mucosal Immune System 
The mucosal immune system is the part of the immune system juxtaposed to the 
mucosal surfaces and in direct contact with the external antigenic environment. It is 
composed of the lymphoid tissues that are associated with mucosal surfaces (MALT or 
mucosa-associated lymphoid tissue) which respond to antigens at the mucosal surfaces 
and can be separated into several components: gut associated lymphoid tissue (GALT), 
bronchus-associated lymphoid tissue (BALT), nasopharinx-associated lymphoid tissue 
(NALT), the MALT is mainly composed of gut-associated lymphoid tissues (GALT) 
lining the GI tract including the lamina propria (contain B cells, plasma cells, activated 
TH cells, and   macrophages) and Peyer‟s patches (contain both B cells and CD4+ T-
cells)  (Chandran, Satthaporn et al. 2003). Peyer‟s patches is composed of specialized 
epithelial cells called M cells. The epithelial cell plays an important role in promoting 
the immune response by delivering foreign antigen from the lumina of the respiratory, 
digestive, and urogenital tracts to the underlying mucosal-associated lymphoid tissue. 
This antigen transport is carried out by specialized M cells (Thomas J. Kindt 2000). 
After encountering by antigen, lymphocytes migrate to the systemic circulation, where 
their further maturation and differentiation completes (Cheroutre and Madakamutil 
2004). These differentiate deffectors memory mammary and salivary glands and the 
genitourinary organs (Kelsall BL 1996) cells migrate back to the mucosa and wait for 
antigen. This is regulated by the coordinated interaction various cell surface molecules 
on the T cell and respective ligands on the contraluminal surface of GI tract (Cheroutre 
and Madakamutil 2004). T cells expressing α4β7- integrin, αEβ7-integrin and C-C 
chemokine receptor 9 (CCR9) are perhaps the best characterized in terms of homing 
potential to the GI tract. 
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Figure 1.11: Organization of the Mucosa Associated Lymphoid Tissues (MALT) 
(Nature reviews Immunology April 2004; 4(4):290-300.3).  In this figure, HEV (High 
Endothelial Venule), the ligand for α4β7-integrin is mucosal vascular–addressin cell-
adhesion molecule 1 (MAdCAM-1), ligand for αEβ7-integrinis E-cadherin and C-C 
chemokine receptor 9 (CCR9) binds with CC-chemokine ligand 25 (CCL-25). 
The mucosal immune system has three main functions (Holmgren and Czerkinsky 
2005): to protect the mucous membranes against colonization and invasion by 
potentially dangerous microbes that may be encountered, to prevent uptake of 
undegraded antigens including foreign proteins derived from ingested food, airborne 
matter and commensal microorganisms, and to prevent the development of potentially 
harmful immune responses to these antigens if they do reach the body interior. As V. 
cholerae is an intestinal pathogen, mucosal immunity plays an important role against 
this pathogen.  
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1.8.5. Immunological Memory 
Immunological memory can be defined as the altered response of a host that follows re-
exposure to the same antigen. It is an operational property of the host and the immune 
system. Generation of immunological  memory  following  contact  with  pathogens  is 
antigen-specific  and  reflects  a  combination  of  humoral („antibody‟)  and  cellular  
immunity,  which  is  often  lifelong (van Leeuwen, Sprent et al. 2009). Memory B cell 
and Memory T cells are two major component of immunological memory. 
1.8.5.1. Memory B cell 
Memory B cell pathway is a complex developmental process that occurs in germinal 
centers and emerges after isotype switching and hypermutation of the immunoglobulin 
genes (R. W. Dutton 1998 ). Thus, after initial contact with antigen, some of the B cells 
participating  in  the  primary  response  mature into  memory  cells; generation of these 
cells is the end result of clonal expansion,  differentiation  and  affinity  maturation.  
These „primed‟ B cells are more efficient than naïve B cells and give heightened 
humoral responses on secondary contact with the antigen concerned. Memory B cells 
may also play a role in replenishing the pool of long-lived plasma cells to maintain long-
term antibody levels in the absence of pathogen (Kenner JR 1995) (Cabrera, Martinez et 
al. 2006)
. 
Long-lived plasma cells are responsible for the continuous maintenance of 
serum antibody levels (Sanchez and Holmgren 1989) (Kenner JR 1995) (Longini, Nizam 
et al. 2007)
. 
Therefore, memory B cells and long-lived plasma cells are responsible for 
the long-term humoral immunity elicited by most vaccines (Levine and Kaper 1993).  
1.8.5.2. Memory T cell 
T cells have an essential role in protection against a variety of infections. Since the case 
for a memory T cell is less clear, no special anatomical site has been identified where 
memory T cells develop; no isotype switching of the T cell receptor genes occurs; and 
no advantageous somatic mutations selected for higher affinity have been observed (van 
Leeuwen, Sprent et al. 2009). It has been studied that the CD4+ T cell population may 
be divided into four major subsets based on surface phenotype and function: resting, 
primed, effector and multifunctional (Mf) (Bell and Westermann 2008). After migration 
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from the thymus, CD4+ T cells join the recirculating pool and represent a population of 
resting CD4+ T cells (inexperienced, naive) (Bell and Westermann 2008). During the 
first encounter with antigen, specific T cells turned to short-lived, metabolically active 
primed T cells. It is also clear that the frequency of memory T cells specific for 
particular antigenic epitopes correlates closely with the extent of proliferation (clonal 
burst size) of the precursor cells during the primary response (Hou, Hyland et al. 1994). 
A second encounter with antigen transforms primed T cells into terminally 
differentiated; cytokine-secreting effector T cells (Seddon, Tomlinson et al. 2003). On 
the contrary, if primed T cells fail to find specific antigen, they modify their cytokine 
capabilities to become Mf T cells with a slightly extended lifespan. Mf T cells may 
respond rapidly to new or residual antigen, proliferate rapidly and add to the number of 
primed T cells. These intermediate T cells produce several different cytokines in 
different quantities as cytokine mRNA decays and new transcripts emerge (Anderson 
2008). In the absence of antigen, Mf T cells default to antigen experienced (Ag-Exp) 
resting T cells that retain no memory of a previous antigen encounter. The Mf T cells 
reacquire the potential to recirculate through lymph nodes (LNs) (Springer 1994) (Zaph, 
Rook et al. 2006) and respond rapidly should they re-encounter antigen (Sallusto, Lenig 
et al. 1999). Such T cells are currently named as central memory. 
 
 
Figure 1.12: Generation of Memory T-cell (Bell and Westermann 2008) 
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1.8.6. Effects of Natural Infection to V. cholerae 
Natural infection to V. cholerae provides long-term protection against subsequent disease 
(Cash, Music et al. 1974) (Koelle, Rodo et al. 2005) (Levine, Black et al. 1981). But the 
mechanism of protective immunity is not well understood yet. The protection may be 
mediated by anamnestic immune responses to V. cholerae antigens (Harris, Bhuiyan et al. 
2009) (Nelson, Harris et al. 2009) (Svennerholm, Jertborn et al. 1984). Different 
components of the immune system, both humoral and cell mediated become activated in 
response to natural V. cholerae infection, suggested by studies to-date in patients with 
cholera (Qadri, Mohi et al. 1995) (Asaduzzaman, Ryan et al. 2004) (Qadri, Bhuiyan et al. 
2004).  
1.8.6.1. Innate Immune Response to V. cholerae 
Cholera is thought to be a prototypical non-inflammatory infection. During acute cholera 
infection a broader range of innate immune mechanisms are activated in the intestinal 
mucosa, both in the epithelium and in lamina propria cells (Flach, Qadri et al. 2007). 
Already it has been noted that increased infiltration of neutrophils, degranulation of mast 
cells and eosinophils, and production of some innate defense molecules occur during 
acute cholera infection although there is no pronounced inflammation during cholera 
(Mathan, Chandy et al. 1995) (Qadri, Raqib et al. 2002) (Asaduzzaman, Ryan et al. 
2004).  It has been showed that innate factors, including myeloperoxidase, lactoferrin, 
nitric oxide metabolites, and eicosanoids are also induced to increase in V. cholerae 
infection (Cash, Music et al. 1974) (Qadri, Raqib et al. 2002).  
1.8.6.2. Adaptive Immune Responses to V. cholerae 
After the initiation of immune response to cholera by presenting the antigen in the 
Payer‟s patches of the gastrointestinal mucosa, stimulated antigen specific B cells 
migrate to the regional lymph node and differentiate into specific antibody secreting 
cells (Qadri 1997). Furthermore, robust systemic and mucosal antibodies are produced 
to the V. cholerae lipopolysaccharide, to cholera toxin, and to colonization factors, 
including the major subunit of the toxin-coregulated pilus, TcpA (Qadri 1997) (Levine 
1979) (Asaduzzaman, Ryan et al. 2004) where the intestinal IgA antibodies are the 
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major immunoglobulin in mucosal immune response (Jertborn 1984 ) (Brandtzaeg 
1986). This locally produced antibody in the intestinal mucosa further secret onto the gut 
mucosal surface. However, after natural infection, the serum levels of these antibodies 
wane more rapidly than protective immunity (Harris 2008).   
1.8.6.2.1. Humoral Immune Response to V. cholerae 
The vibriocidal antibody is considered as a surrogate marker of a protective mucosal 
immune response. Antibodies directed against Vibrio O polysaccharide antigens are 
considered "vibriocidal" antibodies because they will lyse V. cholerae cells in the 
presence of complement and serum components (Levine MM 1993) (Tacket CO and G 
1999) (Harris 2008) (Saha D 2004) . It can be used to determine if a person has 
developed antibodies against V. cholerae, either by exposure to infectious V. cholerae or 
as a result of oral cholera vaccine administration. LPS elicits a variety of inflammatory 
responses in an animal and it activates complement by the alternative (properdin) 
pathway, so it may be a part of the pathology of gram-negative bacterial infections 
(Kenneth Todar 2012). 
Patients with cholera respond with LPS-specific antibodies in the IgG, IgM, and IgA 
isotypes (Qadri, Ahmed et al. 1999) (Qadri F 1997) (Provenzano D 2006). It has been 
studied in Bangladesh that every 2-fold increase in vibriocidal titer is associated with a 
44% decrease in the subsequent risk of cholera (Mosley WH et al. 1969). 
1.8.6.2.2. Cell-mediated Immune Response to V. Cholerae  
Cholera patients mount a primed T-cell response in the mucosa after V. cholerae O1 
infection (Bhuiyan, Lundin et al. 2009). The protection from cholera may be mediated 
by memory B cells which is capable of an anamnestic response in the gut mucosa and 
may depend on stimulation provided by memory T cells for their development and 
maintenance. T cells may contribute to the activation of B cells during V. cholerae 
infection by secreting stimulatory cytokines and direct contact with B cells in lymph 
nodes. Thus, T cells may have an important role in protective immunity to V. cholerae 
infection (Weil, Arifuzzaman et al. 2009). 
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It has been shown that the mucosal immune response to cholera toxin is T-cell 
dependent where, CD4+ T helper cells have an important role and it is established by 
studies with experimental animals (Elson 1987) (Hirabayashi 1991). Though the 
increased proliferative responses of CD4+ and CD8+ T cell has been shown at the acute 
stage of infection , their differences in the kinetics is not clear . However, it is possible 
that these differences may be due to the requirement for CD4+ T cells to help for 
activativation of CD8+ T cells (Bhuiyan, Lundin et al. 2009). They mediate their 
performance by enhanced production of IFN-γ (Th1 response) and IL-13 (Th2 response) 
(Bhuiyan, Lundin et al. 2009). Memory B-cell responses to T-cell-dependent antigens 
(such as CTB) persist for at least 1 year, whereas response to lipopolysaccharide, a T-
cell-independent antigen, wane more rapidly after infection (Weil, Arifuzzaman et al. 
2009). Therefore, the induction of CD4+ T-cell responses might be critical to the 
subsequent development of memory-B-cell responses and for long-term protective 
immunity following cholera.  
1.9. Vaccination 
1.9.1. Development of vaccines to prevent Cholera 
An ideal vaccine for cholera would be very beneficial in the control of morbidity and 
mortality secondary to infection. Present vaccines in the market cannot give protection 
efficiently as natural infection. Natural infection with V. cholerae provides greater than 
90% protection against subsequent disease for at least 3 years in U.S. volunteer studies 
(the maximum period studied) and an average of 3 to 8 years on the basis of 
epidemiological studies in endemic areas (Cash 1974) (Koelle, Rodo et al. 2005) 
(Levine and Kaper 1993) (Black 1982). Therefore, a vaccine which will render long 
lasting immunity is necessary for immune protection of cholera. The aim of cholera 
vaccination is to reduce the case fatality rate to less than 1%. An added prequisite is that 
the vaccine should contain components which can stimulate an appropriate memory 
response which involves both B and T lymphocytes. 
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1.9.2. T Cell based Immunization 
 
As newly emerging and well-established infectious diseases have rekindled a drive to 
explore CD4+ T-cell memory, there is now an urgent need to understand the 
fundamental mechanisms that underpin CD4+ T-cell memory and to develop more 
effective vaccines (Bell and Westermann 2008).  
 Moreover, studies with experimental animals have shown that the mucosal immune 
response to cholera toxin is T cell dependent and that CD4
+
 helper T cells have an 
important role  (Elson and Ealding et al. 1984) (Hirabayashi 1991) (Hirabayashi, 
Tamura et al.; Holmgren 1987) (Holmgren, Svennerholm et al.). CD4
+
 and CD8
+
 T cells 
also increase in the circulation of cholera patients (Bhuiyan, Lundin et al) (Flach, Qadri 
et al. 2007). 
 
 
 
 
Figure 1.13: Individuals at different stages of immunity. (Bell and Westermann 
2008) 
 
  Development of humoral responses to protein antigens is dependent on T-cell responses 
(Qadri, Mohi et al. 1995). Memory T cell response also produced in systemic circulation 
of V. cholera O1 infected patients against VCC and MP (Weil, Khan et al. 2009). 
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Before immunization the naive CD4+ T cells are found in low frequency. After 
vaccination (recently immunized), the naive T cells proliferate and becomes primed 
providing individuals a long term immunity (Fig.1.13).  
Thus, long-term immunological memory is primarily supported by increased numbers of 
long-lived, resting, antigen-specific CD4+ T cells (Homann, Teyton et al. 2001) (Varga 
and Welsh 1998) of specific CD4 T cells (Bell and Westermann 2008). Epitope plays an 
important role in the development of a candidate vaccine. So the identification of the 
epitope recognized by CD4+ T cell or CD8+ T cells can be used as a tool to identify new 
antigen for the development of vaccine (Buus 1999) (De Groot, Ardito et al. 2009) 
(Doolan, Southwood et al. 2003) (Lauemoller, Kesmir et al. 2000) (Khan, Zaman et al. 
2014).  
1.9.3. Oral Cholera Vaccine 
To date, two types of oral cholera vaccines are available, which have been shown to be 
safe, immunogenic and effective- inactivated vaccines (containing killed whole cells of 
V. cholerae) and live attenuated vaccines (containing genetically modified non-
pathogenic strains of V. cholerae) (Sallusto, Lanzavecchia et al. 2010). These vaccines 
have been licensed in some countries and are mainly used by travelers, but are now 
under consideration for use in public health  (Glass, Becker et al. 1982). 
 WC-rBS(Dukoral®): A monovalent inactivated vaccine containing killed whole 
cells of V. cholerae O1 plus additional recombinant cholera toxin B subunit 
(Finkelstein 1996) (bacteriology) (Bradford A. Kay) (Snyder JD 1981).   
 BivWC (Shanchol®): A bivalent inactivated vaccine containing killed whole 
cells of V. cholerae O1 and V. cholerae O139 (Anh, Canh do et al. 2007) 
(Mahalanabis, Lopez et al. 2008). 
 BivWC (mORCVAX®): A bivalent inactivated vaccine containing killed whole 
cells of V. cholerae O1 and V. cholerae O139. Produced by VABIOTECH, 
Vietnam and only available in Vietnam (WHO 2009). 
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 CVD103-HgR: A live attenuated genetically modified V. cholerae O1 Inaba 
strain and engineered to produce CTB but not the A subunit of CT (Richie, 
Punjabi et al. 2000). 
 
 Peru-15: Peru-15 is a Vibrio cholerae O1 E1 Tor, Inaba strain that has been 
engineered to be non-toxinogenic (it lacks the ctxA and rtxA genes, which encode 
cholera toxin A subunit and the RTX toxin, respectively), non-recombinatorial (it 
lacks the recA gene and the attachment site for the CTX phage), non-motile, and 
ctxB positive (it makes the immunogenic, nontoxic CTB subunit (Richie, Punjabi 
et al. 2000). 
 
1.9.4. Shanchol™  
Shanchol™ is a new oral, killed, bivalent, whole-cell cholera vaccine developed through 
International Vaccine Institute (IVI) with funding from the Bill & Melinda Gates 
Foundation, the Government of Korea, and the Swedish International Development 
Cooperation Agency (SIDA) by simply modifying a vaccine used and produced in 
Vietnam, in response to the need for a low-cost cholera vaccine for the developing world 
International Vaccine Institute (IVI) transferred the technology to Shantha Biotechnics, 
India and it was licensed in 2009 as Shanchol and prequalified by the WHO in 2011 so 
that it meets international Good Manufacturing Practice (GMP) standards and WHO 
production guidelines (Sanofi 2009). 
The vaccine has some major advantages over the only other cholera vaccine currently on 
the market (Dukoral®). Firstly, it contains no cholera toxin B subunit. There is no 
chance of degradation of antigen by gastric acid. 
So it does not require administration with a buffer, thereby it greatly simplifying its use 
under field conditions and other post-crisis situations. Secondly, it will be available to 
governments and international agencies at low cost $1.85 per dose. Thirdly, a phase III 
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trial taking place in India is showing that the vaccine is more effective and lasts 67% 
efficacy in young children (1-5 years old) comapared to Dukoral® (Sanofi 2009). 
In comparison, within 6 months of vaccination the protective efficacy of two- and three-
dose regimens of the Dukoral vaccine was 85% in Bangladesh (Clemens, Sack et al. 
1986) and Peru (Sanchez, Vasquez et al. 1994), however this protection falls to 50% 
within 3 years (Clemens, Sack et al. 1990). 
 
 
 
Figure 1.14: Shanchol Vaccine (https://www.ivi.org) 
 
On the contrary, Kolkata field trial of Shanchol vaccine revealed comparable levels of 
protective efficacy in children <5 years and adults during 2-year period of observation 
(Sur, Lopez et al. 2009). 
In Bangladesh, previous study had been done to show the temperature stability of 
Shanchol vaccine and it was found that the vaccine was effective without maintaining 
the controlled temperature. Currently this study conducted to show the immune response 
of oral cholera vaccine Shanchol in Bangladeshi adult recipients. 
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1.10. Objectives of the Study 
1.10.1. General Objective 
To assess the efficacy of Shanchol vaccine to generate immunological responses in the 
vaccine administered volunteers 
1.10.2. Specific Objectives 
The specific objectives of this study are as follows: 
 To evaluate the involvement of different subsets of T cells like CD4+ T cells, 
CD8+ T cells and their memory responses in vaccinees after administration of 
one and two doses of vaccine. 
 To compare the memory T cell responses in vaccinees using different vaccine 
administration strategies like administration at 14 days or 30 days apart in case 
of two doses of vaccination. 
 To evaluate B-cell mediated long lasting protection efficacy of vaccine.  
 To evaluate the durability of vaccine specific memory T-cell responses. 
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2.1. Study Design 
The study was conducted from November 2012 to January 2014.  
 
 
 
   
                                                      
  
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 2.1: Flow chart of the Study 
 
 
 
Enrollment of Healthy 
Study Participants 
Administration of different doses of 
vaccine 
Blood Collection at different days d0, d3, 
d7, d14, d17, d30, d33, d42, d60, d90  
 
Whole Blood Separation of cells and plasma, 
from Blood  
 FASCIA using different 
antigens 
Evaluation of memory T cell 
responses 
Vibriocidal Antibody Assay 
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2.2.1. Location of the Study 
Blood sample was collected from urban slum of Mirpur, Dhaka, Bangladesh. The 
immunological work resembling flow cytometric assays with heparinized whole blood 
for measuring T-cell responses and plasma for vibriocidal assay were carried out in the 
immunology laboratory unit of the Centre for Vaccine Sciences (CVS), iccdr,b, Dhaka. 
The Research Review Committee (RRC) and Ethical Review Committee (ERC) of 
icddr,b approved the study protocol. The human experimentation guidelines of the U.S. 
Department of Health and Human Services were followed during the study. Oral and 
written informed consent were obtained from adult participants in all instances.  
2.2.2. Study Participants 
A total number of 45 healthy adults were enrolled in this study. The healthy participants 
were divided into 3 groups depending on vaccine doses. 15 participants were given a 
single dose of the Shanchol vaccine, and 15 participants were given two doses at 14 days 
interval, while the rest 15 participants were given two doses at 30 days interval.   
2.3. Vaccination 
Before vaccination, participants were excluded from the study if they had a history of 
gastrointestinal disorder or diarrhoeal illness in the past 2 weeks, febrile illness in the 
preceding week or having history of receiving antibiotic treatment at least 7 days prior to 
enrolment, immunocompromising condition or therapy, intake of anti-diarrheal 
medication or acute disease in the past week or that were positive for common enteric 
pathogens. Participants who had ever taken killed OCV or any live or killed enteric 
vaccine in the last month prior to vaccination were also excluded. 
2.3.1. Vaccine components 
Shanchol™ is an oral, killed, bivalent whole-cell cholera vaccine developed by Shantha 
Biotechnics, India and it was licensed in 2009 in India and prequalified by the WHO in 
2011. Again, it meets international Good Manufacturing Practice (GMP) standards and 
WHO production guidelines (Shantha 2011).  
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Figure 2.2: Shanchol Vaccine. (https://www.ivi.org) 
 
Each dose of the Shanchol (Shantha Biotechnics) vaccine in 1.5 mL contained heat killed 
and formalin killed whole cell bacteria consisting of 600 ELISA Units (EU) of 
lipopolysaccharide (LPS) of formalin-killed V. cholerae O1 Inaba, El Tor biotype (strain 
Phil 6973). It also contains 300 EU LPS of heat-killed V. cholerae O1 Ogawa classical 
biotype (Cairo 50); 300 EU LPS of formalin killed V. cholerae O1 Ogawa classical 
biotype (Cairo 50); 300 EU LPS of heat killed V. cholerae O1 Inaba, classical biotype 
(Cairo 48) and 600 EU LPS of formalin killed V. cholerae O139 (4260B) (Sur, Lopez et 
al. 2009) (Mahalanabis, Lopez et al. 2008). 
 
2.3.2. Administration of vaccine 
 
The participants included in the study were instructed not to eat for 1 h before and after 
intake of vaccine and were requested to wait at the field clinic for half an hour to monitor 
the side-effects. Before opening the vaccine vial, field assistant rotated the vial gently to 
disperse the cellular contents. Following administration, the participants were offered half 
a cup of water {(Saha et al. 2009). 
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2.4. Blood Collection Scheme  
Administration of vaccine was done using different dose patterns to evaluate the 
immunogenicity in study participants which are as follows: 
2.4.1. Single Dose Vaccination 
 
Figure 2.3: Before vaccination blood was collected from study participants and marked as day 
point 0 (d0). After administration of single dose of vaccine blood samples were collected at d3, 
d7, d30, d90.  
2.4.2. Double Dose Vaccination 14 Days Interval 
 
Figure 2.4: After administration of 1
st
 dose of vaccine at day 0, second dose of vaccine was given 
at 14 days apart and blood was collected at different day points d0, d3, d7, d14, d17, d42, d90. 
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2.4.3. Double Dose Vaccination 30 Days Interval 
 
Figure 2.5: After administration of 1
st
 dose of vaccine at day 0, second dose of vaccine was given 
at 30 days apart and blood was collected at different day point‟s d0, d3, d7, d30, d33, d60, d90. 
Approximately, 0.5ml venous blood sample was collected in lithium heparin tube to 
assess memory T cell responses. About 3 ml of blood sample was taken in vials, not 
containing additives, for serum collection at day 3 of each vaccination and plasma was 
collected on other days. Using density gradient centrifugation at 750g, 20°C for 10 mins 
and was stored at -20C for ELISA and vibriocidal assay. 
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2.5. Laboratory Methods 
2.5.1. Flow Cytometric Assay of Specific Cell-mediated Immune Response in 
Activated Whole Blood (FASCIA) 
FASCIA (flow cytometric assay of specific cell-mediated immune response in activated 
whole blood), a simple and reproducible method was used to determine lymphoblast 
formation in response to antigenic stimulation (Parment, Svahn et al. 2003) (Weil, 
Arifuzzaman et al. 2009).  
T- Cell stimulating antigens V. cholerae O1 specific membrane preparation (MP) and 
mutant cholera toxin (mCT) was used. A plant derived protein phytohaemagglutinin 
(PHA) (1 µg/ml; Murex, Remel, Sweden) was used as a positive control and 
nonstimulated culture was used as negative controls (Kuchta, Rahman et al.).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure.2.6: Graphical representation of FASCIA method 
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2.5.1.1. Antigen Preparation 
Membrane Preparation (MP) 
MP contains a mixture of bacterial proteins and it is composed of mostly outer membrane 
protein U precursor porin OMPU, elongation factor, chaperonin, ATP synthase subunit α, 
β, some other different enzymes etc. (Weil, Arifuzzaman et al. 2009).  
V. cholerae MP was made from the sequenced O1 El Tor strain N16961 grown in vitro in 
AKI medium (Iwanaga and Yamamoto 1985). Specifically, a culture of N16961 was 
inoculated into 1 liter of AKI medium (Iwanaga and Yamamoto 1985). The culture was 
grown in nonaerating conditions to an optical density of 0.3 at 600 nm and then 
transferred to shaking conditions for growth to stationary phase. Bacterial pellet was 
collected after centrifugation and then sonicated. The sonicated mixture was centrifuged 
at 1,400 × g for 10 min, and the remaining supernatant was then centrifuged at 14,900 × g 
for 30 min. The pellet containing the membrane fraction was then suspended in MgCl2-
Tris buffer (5 mM MgCl2, 10 mM Tris [pH 8.0] ) for subsequent experiments.  
Mutant Cholera Toxin (mCT)  
Mutant cholera toxin contains the G33D variant homopentameric B subunit (mCT) 
(Wolf, Jobling et al. 2008). The mCT protein contains a G33D substitution in the B 
subunit binding domain that prevents the molecule from binding GM1 ganglioside (Wolf, 
Jobling et al. 2008). The mutant Cholera Toxin antigen (G33D holotoxin) has a single 
amino acid substitution (Gly-33→Asp) in the binding site for GM1 ganglioside (Jobling 
and Holmes 1991) due to a single point mutation. The FASCIA response is stronger to 
mutant CT (mCT) B subunit than unaltered CT (Ahmed, Arifuzzaman et al. 2009).   
PHA 
Phytohaemagglutinin (PHA) is a lectin found in plants, especially in legumes. PHA 
actually consists of two closely related proteins, called leucoagglutinin PHA-L and PHA-
E. The letters „E‟ and „L‟ indicate these proteins agglutinate Erythrocytes and 
Leukocytes. Phytohaemagglutinin has carbohydrate-binding specificity for a complex 
oligosaccharide containing galactose, N-acetylglucosamine, and mannose (Summers et 
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al. 2002). It is used as a mitogen to trigger cell division in T-lymphocytes. Hence 
lymphocytes cultured with Phytohemagglutinin can be used for ex vivo T-cell 
proliferation. 
NS 
Dulbecco modified Eagle (DMEM) medium with supplementation with 10% FBS, 1% 
Gentamycin and 1% Mercaptoethanol is used as non stimulating medium. 
2.5.1.2. Protocol 
1. Whole blood was collected in a lithium heparin-coated tube and diluted 1:8 in 
Dulbecco modified Eagle medium (DMEM) (Gibco, NY) supplemented with 1% 
gentamycin (Sigma), 1% mercaptoethanol, 10% heat-inactivated fetal bovine 
serum (FBS) (Gibco BRL- 16140-071) and DMEM-rest. 
2. 0.4 ml of diluted blood was added to each 5 ml polystyrene FACS tubes (Becton 
Dickinson, San Jose, USA). 
3. 100µL of stimulating antigen, control antigen, or additional medium was added to 
400 µL of diluted blood. The final concentrations of each stimulatory antigen and 
the control antigen were 10 and 1 µg/ml, respectively. 
4. The tubes were incubated at 37oC in 5% CO2 for 6 days. 
5. After 6 days of in vitro culture in an atmosphere containing 5% CO2 at 37°C, the 
tubes were centrifuged for 5 min at 400×g. 
6. We recovered the culture supernatant by centrifugation, mixed it with a protease 
inhibitor and then stored this at ˗70°C for subsequent cytokine analysis. 
7. The pellet of whole blood cells were stained directly with fluorochrome 
conjugated monoclonal antibody cocktail having anti-CD3-FITC, anti-CD4-
PerCP, anti-CD8-APC, and anti-CD45R0-PE (Becton Dickinson 
Immunocytometry Systems [BD], Stockholm, Sweden) and incubated for 15-20 min 
in darkness at room temperature. 
8. 2 ml of an erythrocyte lysing solution of ammonium chloride (sigma) containing 
potassium chloride and EDTA was added to each tube. Tubes were vortexed and 
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another 1 ml of ammonium chloride was added. Then tubes were incubated for 5 
min in dark at room temperature. 
9. At 400×g, tubes were centrifuged for 5 min and the supernatants were removed 
immediately. 
10. 3 ml of FACS buffer was added to each tube and mixed by vortexing. Afterward, 
tubes were centrifuged for 5 min at 400×g and the supernatants were discarded. 
11. 400 l cell fixative (Becton Dickinson, San Jose, USA) was added to each tube, 
mixed and stored in the dark until acquisition. 
12. Acquisition was conducted by fluorescence-activated cell sorting (FACS Calibur, 
Becton Dickinson, San Jose, USA) for standardized acquisition time of 2-min 
using CellQuest Pro software (Becton Dickinson, San Jose, CA) within 12h. All 
events acquired during 120 s acquisition time were saved. 
13. Analysis was performed with FlowJo software (TreeStar, Inc. Oregon). The 
results are presented as the ratio of lymphoblast count with antigenic stimulation 
to the count without stimulation (stimulation index). A value of “1” indicates that 
stimulation is equal in samples with or without V. cholerae antigenic stimulation. 
 
Table 2.1: FASCIA Antigen preparation 
Antigen Stock 
concentration 
Working  
concentration 
5X Amount (in 
DMEM complete) 
(For FASCIA) 
MP 8.3 mg/ml 10 g/ml 3.0 l for 500 l 
G33D  
Holotoxin 
8. 04 mg/ml 10. 0 µg/ml 3.2 l for 500 l 
PHA 2 stock-200 g/ml 
(1 stock-2 mg/ml) 
1 g/ml 5.0 l for 500 l 
NS    
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Table 2.2: Fluorochrome tagged antibody specifications 
Fluorochrome tagged 
antibody 
Fluorescence 
emission color 
Ex-max
a
 
(nm) 
Em-max
b
 
(nm) 
Company 
anti-CD3-allophycocyanin 
(anti-CD3-APC) 
 650 660 BD
c
 
anti-CD4-peridinin 
chlorophyll protein 
(anti-CD4-PerCP) 
 482 678 BD 
anti-CD8-fluorescein 
isothiocyanate 
(anti-CD8-FITC)  
494 519 BD 
anti-CD45RO- 
phycoerythrin 
(anti-CD45RO-PE) 
 496, 546 578 eBioscience 
Ex-max
a
- Escitation maxima, Em-max
b
- Emission maxima,  
BD
c- 
Becton Dickinson, San Jose, USA 
 
2.5.1.3. An Overview of the Flow Cytometry 
Flow cytometry is a technique for counting, examining, and sorting microscopic particles 
suspended in a stream of fluid. In the flow cytometer, particles are carried to the laser 
intercept in a fluid stream. Any suspended particle or cell from 0.2–150 micrometers in 
size is suitable for analysis. The properties measured include a particle‟s relative size, 
relative granularity or internal complexity, and relative fluorescence intensity. Flow 
cytometers use the principle of hydrodynamic focusing for presenting cells to a laser (or 
any other light excitation source). A flow cytometer is made up of three main systems: 
fluidics, optics, and electronics. The fluidics system transports particles in a stream to the 
laser beam for interrogation. The optics system consists of lasers to illuminate the 
particles in the sample stream and optical filters to direct the resulting light signals to the 
appropriate detectors. The electronics system converts the detected light signals into 
electronic signals that can be processed by the computer. For some instruments equipped 
with a sorting feature, the electronics system is also capable of initiating sorting decisions 
to charge and deflect particles. 
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Figure 2.7: Acquisition of FASCIA cultured lymphocyte populations (© 2014, Max Planck 
Institute for Marine Microbiology) 
A fluorescent compound absorbs light energy over a range of wavelengths that is 
characteristic for that compound. This absorption of light causes an electron in the 
fluorescent compound to be raised to a higher energy level. This energy is released as a 
photon of light with specific spectral properties unique to different fluorochromes. This 
transition of energy is called fluorescence. The argon ion laser is commonly used in flow 
cytometry because the 488-nm light that it emits excites more than one fluorochrome. 
 
Table 2.3: Quanta of Fluorochrome Fluorescence (http://www.seci.info/.pdf) 
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2.5.1.4. Acquisition of Cells 
Following staining, cells were washed and fixed in cell fix (Becton Dickinson, San Jose, 
USA) to stabilize the cells before flow cytometry was performed. Cells were stained with 
fluorescent markers, allophycocyanin-(APC), peridinin chlorophyll protein- (PerCP), 
fluorescein isothiocyanate – (FITC), phycoerythrin-(PE) conjugated with anti-CD3, anti-
CD4, anti-CD8 and anti-CD45RO respectively. Acquisition was performed on a FACS 
caliber flow cytometer (Becton Dickinson, San Jose, CA, USA) and viable cells were 
analyzed with CellQuest Pro multipurpose software (version 3.3; Becton Dickinson, San 
Jose, U.S.A). 
Sorting allows us to capture and collect cells of interest for further analysis. To sort 
particles or cells, the cytometer first needs to identify the cells of interest, then separate 
out the individual cells. Once the population of interest has been identified on a data 
acquisition plot, a region is drawn around that population. A logical gate is created from 
the regions. This gate is then loaded into the cytometer‟s software as the sort gate. The 
sort gate identifies cells of interest to be sorted out of the stream. 
Flow cytometric data is stored according to a standard format, the flow cytometry 
standard (FCS) format, developed by the Society for Analytical Cytology. According to 
the FCS standard, a data storage file includes a description of the sample acquired, the 
instrument on which the data was collected, the data set, and the results of data analysis. 
When multiplied by the approximately 10,000 events collected for a single sample, an 
FCS data file typically contains 80 kB of data.  
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2.5.1.5. Analysis of Gating Strategies 
Gating Principles  
A gate in cytometry is a set of value limits (boundaries) that serve to isolate a specific 
group of cytometric events from a large set of data. It is a numerical or graphical 
boundary that can be used to define the characteristics of particles to include for further 
analysis. 
 
 
 
Figure 2.8: Scatter Diagram Morphology (http://www.seci.info/.pdf)  
An important principle of flow cytometry data analysis is to selectively visualize the cells 
of interest while eliminating results from unwanted particles e.g. dead cells and debris. 
Cells have traditionally been gated according to physical characteristics. For instance, sub 
cellular debris and clumps can be distinguished from single cells by size, estimated by 
forward scattering and side scattering light. Also, dead cells have lower forward scatter 
and higher side scatter than living cells. These same principles can be used to distinguish 
different cell populations. 
 
The Flow cytometry (FCM) data were analyzed with FlowJo software (Tree Star Inc., 
version 8.5.3). The lymphocyte population was identified in a forward- versus side-
scatter plot, the different subpopulations were gated according to different staining 
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patterns and results expressed as frequency of expression. T cells were identified based 
on their expression of the CD3+ cell surface marker. Among the CD3 cells, CD4+ and 
CD8+ subpopulation was gated followed by identification of the CD45RO memory cells.  
The ratio is referred to as the stimulation index (SI). An SI value equal to “1” indicates 
that stimulation is equal in samples with or without a V. Cholerae antigen, and “1” 
indicates V. Cholerae antigen-specific stimulation. 
 
  
 
Figure 2.9: Two Parameter Histogram Plot (http://www.seci.info/.pdf) 
 
A quadrant marker divides two-parameter plots into four sections to distinguish 
populations that are considered negative, single positive, or double positive. The lower-
left quadrant displays events that are negative for both parameters. The upper-left 
quadrant contains events that are positive for the y-axis parameter but negative for the x-
axis parameter. The lower-right quadrant contains events that are positive for the x-axis 
parameter but negative for the y-axis parameter. The upper-right quadrant contains events 
that are positive for either parameters, or double positive. 
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Figure 2.9: FACS Plot gating strategy after stimulation with antigens: (A) Cells are 
separated according to forward scattering cells versus side scattering cells. B) T-cells are 
separated by surface marker CD3 (C) Subpopulation of T-cell (Helper-T-cell and 
Cytotoxic T-cells) are separately gated by using surface marker CD4 and CD8 
respectively (D) Memory T-cells (defined as CD4
+
CD45RO
+
) are separated , finally (E) 
Memory T-cells (defined as CD8
+
CD45RO
+
) are separated. 
 
 
A 
B 
C 
D E 
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2.5.2. Vibriocidal Antibody Assay 
2.5.2.1. Vibriocidal Assay 
Vibriocidal antibody assay is considered as the surrogate marker. Vibriocidal antibody assay 
was performed using guinea pig complement with V. cholerae O1 Ogawa (X-25049 El Tor), 
V. cholerae O1 Inaba (19479 El Tor. Inaba) and V. cholera O139 as target organisms. 
Vibriocidal titer was defined as the reciprocal of the highest dilution resulting in >50% 
reduction of the optical density when compared to that of control wells without serum. 
Individuals showing a ≥4-fold increase in vibriocidal antibody titer at day 7 or day 21 after 
vaccination were considered as responders. 
 
 
Figure 2.10: A schematic representation of vibriocidal assay. 
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2.5.2.2. Procedure 
 Vibrio cholerae O1 (Ogawa: strain 25049 El Tor, Inaba: strain 19479 El Tor) 
were cultured overnight on blood agar plates at 37
o
C. 
 A loopful of bacteria from the plates was inoculated in 15 ml Brain Heart Infusion 
(BHI) medium in a conical flask covered with cotton plug. This was incubated on 
a shaker at 37
o
C for next 3-4 h. 
 The culture was centrifuged at 3000 rpm for 10 min and the supernatant was 
discarded. The sediment was further suspended in sterile saline. 
 The suspension was centrifuged for another 8-10 min and pellet was resuspended 
in sterile saline. 
 Bacterial concentration was adjusted by spectrophotometer at 600 nm wavelength. 
For V. cholerae O1 (Ogawa: strain 25049 El Tor, Inaba: strain 19479 El Tor) OD 
was adjusted at 0.3. 
 Heat-inactivated (56oC plus 30 min) plasma was diluted 2-fold in sterile saline in 
flat bottom micro titer plates (Nunc, F) as stated below: 
 25 µl of cold saline was dispensed in all wells except column #2. 
 45 µl of cold saline and 5 µl of test sera were dispensed in column #2.  
The sera was serially diluted (initial dilution 1:10) 2-fold by using a multi 
channel dispenser. The dilution was accomplished by mixing the solution 
in column #2, aspirating 25 µl and dispensing and mixing the sample in 
column #3 and so on, till column #12 (this equals to 1:10240). The last 25 
µl was discarded from the last well on each row. The plates were kept at 
4
o
C (on ice) until used. 
 The indicator (bacteria-complement-saline mixture) was prepared and used 
immediately after preparation. The composition for each plate was as following:   
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Table 2.4: Composition of indicator system 
 
25 µl of the indicator was added to all wells except wells in row A, B, C and D in column 
#1. The plate was incubated on a shaker at 37
o
C for 1 h (50 rpm). 
 150 µl BHI was added to each well. This was incubated for another 3-4 h at 37oC 
without shaking. The plates were read visually and spectrophotometrically. 
Optical density (OD) was measured at 595 nm in the Multiscan Ascent Reader 
(Thermo Labsystems, Denmark). The absorbance for control wells should reach 
0.20 to 0.28 at 595 nm.  
 Vibriocidal antibody titer was defined as the reciprocal of the highest serum 
dilution resulting in greater than 50% OD reduction when compared to the OD of 
control wells without serum. 
 
2.6. Statistical Analysis 
Comparisons of immunological response for significance were tested for significance 
within groups using Wilcoxon Matched Paired t-test, among groups using Mann Whitney 
Rank-sum test. All reported P values were two-tailed and P ≤ 0.05 was considered a 
threshold for statistical significance. Analyses were performed with Graph Pad Prism 5.0 
and Microsoft Excel. 
 
 
   Sterile Saline Bacteria Complement 
V. cholerae O1 (X25049 or19479)   2.55 ml 150 µl 300  µl 
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3.1. Demographics of Study Participants 
The study was conducted to characterize the memory T-cell responses after 
administration of the oral cholera vaccine, Shanchol using different dose pattern such as 
single dose, double dose given at 14 days and 30 days intervals.  In total 45 adult 
vaccinees aged between 18 to 45 years (median age, 30 years) were enrolled and were 
divided into three groups, each group embedded by 15 participants. Same group of 
vaccinees were assessed to study both of their T-cell responses and serological immune 
responses. The number of male and female participants were 2 (5%) and 43 (95%) 
respectively. Among them only two participants were Rh negative. Participants of this 
study did not show any adverse effect after the administration of vaccine. The 
demographic characteristics of the study participants are presented below (Table 3.1).  
  
Table 3.1: Demographics of Study Participants  
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Figure 3.1: ABO Blood Grouping of Study Participants. 
3.2. Memory T-cell Responses by FASCIA 
Memory T-cell responses to multiple V. cholerae antigens of Bangladeshi participants, 
given the oral cholera vaccine Shanchol and its subsets were analyzed by using multi 
parameter flow cytometric assay of specific cell mediated immune response in activated 
whole blood (FASCIA). The FASCIA assay was used to investigate the lymphoblast 
proliferation and responses were observed at different day points using different dose 
patterns of vaccine administration. The results are presented as the ratio of lymphoblast 
count with antigenic stimulation to the count without stimulation (stimulation index). A 
value of “1” indicates that stimulation is equal in samples with or without V. cholerae 
antigenic stimulation (Weil, Arifuzzaman et al. 2009) .  
 
Selection of antigens for T-cell stimulation  
The study included stimulation with V.cholerae O1 specific membrane preparation (MP) 
and modified cholera toxin (mCT) as antigen since previous study showed that MP and 
mCT are highly immunogenic (Weil, Arifuzzaman et al. 2009). 
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3.2.1 Antigen specific CD3+ T-cell responses in vaccinees using different dose 
patterns 
3.2.1.1. CD3+ T-cell responses to MP and mCT in single dose vaccinees  
Proliferative responses of CD3+ T-cell at day 7 to MP were (1.38±1.43) significantly 
(P=0.002) higher (P=0.002) than the day 0 response (0.54±0.33) after the single dose of   
vaccine. On the contrary, CD3+ T-cell stimulation decreased at day 30 and day 90 after 
the single dose. The mean value against MP antigen at day 90 was 0.56±0.24 which was 
significantly lower than day 0 (0.81±0.33). Similarly, the mean value of same pattern of 
stimulation was observed in case of similar T-cell responses against mCT at Day 7 (1.58± 
1.23) which was significantly (P=0.33) higher than day 0 response (0.82±0.36). After day 
7 of vaccination, response to mCT wane down (Fig.3.2). 
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Figure 3.2: Comparison of lymphoblast T-cell response (blast CD3+) to ex vivo 
stimulation of whole blood by V. cholerae MP and mCT antigens at different study days 
in study participants. The response was expressed as Stimulation Index (SI). The study 
days are plotted on X- axis and stimulation index on Y-axis. Each bar represents the 
mean value and the error bar represents the standard error of means (SEM). Paired t-test 
was used for statistical evaluation (*P < 0.05). 
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3.2.1.2. CD3+ T-cell responses to MP and mCT in double dose 14 days apart 
vaccinees  
In case of double dose 14 days apart vaccines,   proliferative responses to MP antigen 
was  significantly higher at day 7 (1.24±1.14)  (P=0.006)  than the baseline at day 0 
(0.75±0.27) (P=0.76). But response decreased after day 7. Similar, responses were 
observed for CD3+ T-cell lymphoblast to mCT antigenic stimulation at day 7 and 
decreased gradually (Fig.3.3) 
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Figure 3.3: Comparison of lymphoblast T-cell response (blast CD3+) to ex vivo stimulation of 
whole blood by V. cholerae MP and mCT at different study days in study participants. The study 
days are plotted on X- axis and stimulation index on Y-axis. The response was expressed as 
Stimulation Index (SI). The dot represents the mean SI value and the error bar represent the 
standard error of mean (SEM). Paired t-test was used for statistical evaluation (*P < 0.05) 
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3.2.1.3 CD3+ T-cell responses to MP and mCT in double dose 30 days apart 
vaccinees  
In this group, double dose of the vaccine was administered 30 days apart and CD3+ T-
cell lymphoblast response was increased gradually up to day 7. The response at day 7 
(1.54±0.85) was significantly (P=0.0003) higher than the baseline value (0.68±0.31) to 
MP antigen. The response was also found significantly (P= 0.025) higher than 3 days 
after second dose of vaccine at day 33 (1.04±0.36).  Stimulation index was decreased 
gradually over the period of day 60 and day 90. Similar responses to mCT was not 
observed (Fig.3.4)  
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Figure 3.4: Comparison of lymphoblast T-cell response (blast CD3+) to ex vivo stimulation of 
whole blood by V. cholerae  MP and  mCT antigens at day 0 (before vaccination), day 3 (3 days 
after first dose of vaccination), day 7, day 33 (3 days after second dose of vaccination), day 42, 
day 90 in adult participants. The study days are plotted on X- axis and stimulation index on Y-
axis. The response was expressed as Stimulation Index (SI). Each bar represents the mean value 
and the error bar represents the standard error of mean (SEM). Paired t-test was used for 
statistical evaluation (*P < 0.05). 
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3.2.2 Antigen specific CD4+ T-cell responses in vaccinees using different dose 
patterns 
3.2.2.1. CD4+ and CD4+/ CD45 RO+ T-cell response to MP and mCT in single dose 
vaccinees  
In response to MP antigen, the lymphoblast helper T cell (CD4+) and memory helper T 
cell (CD4+ CD45RO+) responses were increased after intake of the first dose of 
Shanchol vaccine. The baseline mean value for lymphoblast CD4+ T cell (1.25± 0.91) 
(1.67± 0.92) was significantly increased at day 3 (P=0.047) and day 7 (P=0.001) 
respectively.  Similar pattern of response was found in lymphoblast CD4+/CD45RO+ T-
cell  elevated day 3 (P= 0.030) and day 7 (P=0.0003) responses were  observed in 
response to MP. After day 7 responses was wane down in both lymphoblast CD4+ T cell 
and CD4+/CD45RO+ T -cell over the period day 90.  Similar responses were not 
observed to mCT at any day points. (Fig.3.5) 
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Figure 3.5: Comparison of lymphoblast T-cell response (blast CD4+ and CD4+ CD45RO+) to ex 
vivo stimulation of whole blood by V. cholerae MP and mCT antigens at day 0 (before 
vaccination), day 3 (3 days after first dose of vaccination), day 7, day 30, day 90 in study 
participants. The study days are plotted on X- axis and stimulation index on Y-axis. The response 
was expressed as Stimulation Index (SI). Each bar represents the mean value and the error bar 
represents the standard error of mean (SEM). Paired t-test was used for statistical evaluation (*P 
< 0.05). 
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3.2.2.2. CD4+  and CD4+/ CD45 RO+ T-cell responses to MP and mCT in double 
dose 14 days apart vaccinees  
The baseline SI to MP antigen for lymphoblast CD4+ T-cell and the CD4+ CD45RO+ T-
cell were 0.77±0.44 and 0.74±0.46 respectively. Three days after the first dose of the 
vaccine, the  SI for lymphoblast CD4+ T-cell showed   increasing trend (1.62±1.23) 
which eventually became significant at day 7 (1.42±0.83) compared to baseline. 
Similarly, the memory helper T cell (CD4+/CD45RO+ T cell) response was  significantly 
(P=0.03) higher (1.42±0.83) at day 7 to MP antigen. Three days after the second dose of 
vaccine, SI for both helper (P=0.02) and memory helper (P=0.04) types of lymphoblast 
were also found significantly higher. But, in both cell types, responses decreased. 
However, no   response was observed to mCT at any study day points compared to 
baseline (Fig.3.6). 
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Figure 3.6: Comparison of lymphoblast T-cell response (blast CD4+ and CD4+ CD45RO+) to ex 
vivo stimulation of whole blood by V. cholerae MP and mCT antigens at day 0 (before 
vaccination), day 3 (3 days after first dose of vaccination), day 7, day 17 (3 days after second 
dose of vaccination), day 42, day 90 in adult participants. The study days are plotted on X- axis 
and stimulation index on Y-axis. The response was expressed as Stimulation Index (SI). The dot 
represents the mean SI value and the error bar represent the standard error of mean (SEM). Paired 
t-test was used for statistical evaluation (*P < 0.05). 
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3.2.2.3. CD4+ and CD4+/ CD45 RO+ T-cell response to MP and mCT in double dose 
30 days apart vaccinees  
  A gradually increasing trend of responses for CD4+ lymphoblast and the 
CD4+/CD45RO+ T cell lymphoblast was found at day 3, day 7 in vaccinees after 
administration of first dose of the vaccine. The baseline SI for CD4+ lymphoblast and the 
CD45RO+ lymphoblast were (0.67± 0.32) and (0.64±0.33 ), three days after 
administration of first dose vaccine, the SI for CD4+ T cell and the CD4+/CD45RO+ T 
cell lymphoblast were (1.22±0.57) and (1.16± 0.58) respectively which were significant 
in comparison to the baseline.  At day 7, more significant SI for both populations were 
observed with the mean value (1.71±1.28) for CD4+ lymphoblast and (1.70± 1.33) for 
CD4+/CD45RO+ lymphoblast. After the second dose of the vaccine, vaccinees also 
showed significant elevated responses for lymphoblast CD4+ T cell and lymphoblast 
CD4+/CD45RO+ T cell to MP antigen. However, in both helper and memory helper cells 
cellular responses to MP and mCT decreased after three days of second dose of vaccine. 
mCT responses at different days were elevated than MP specific responses. (Fig.3.7). 
CD 4+ T Cells
D
0
D
3
D
7
D
33
D
60
D
90 D
0
D
3
D
7
D
33
D
60
D
90
0.0
0.5
1.0
1.5
2.0
2.5
D0
D3
D7
D33
D60
D90
*
** ***
MP mCT
C
D
4
+
 T
 c
e
ll
s
S
ti
m
u
la
ti
o
n
 I
n
d
e
x
 (
S
I)
CD4+ CD45RO+ T Cells
D
0
D
3
D
7
D
33
D
60
D
90 D
0
D
3
D
7
D
33
D
60
D
90
0.0
0.5
1.0
1.5
2.0
2.5
D0
D3
D7
D33
D90
D60
MP mCT
*
** ***
C
D
 4
+
 C
D
4
5
 R
O
+
 T
 C
e
ll
s
S
ti
m
u
la
ti
o
n
 I
n
d
e
x
(S
I)
        
Figure 3.7: Comparison of lymphoblast T-cell response (blast CD4+ and CD4+ CD45RO+)) to 
ex vivo stimulation of whole blood by V. cholerae MP and mCT antigens at day 0 (before 
vaccination), day 3 (3 days after first dose of vaccination), day 7, day 33 (3 days after second 
dose of vaccination) day 60 and day 90 in adult participants. The study days are plotted on X- 
axis and stimulation index on Y-axis. The response was expressed as Stimulation Index (SI). 
Each bar represents the mean value and the error bar represents the standard error of means 
(SEM). Paired t-test was used for statistical evaluation (*P < 0.05). 
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3.2.3 Antigen specific CD8+ and CD8+/CD45RO+ T-cell response at different 
dose pattern 
3.2.3.1. CD8+ and CD8+/CD45RO+ T-cell response to MP and mCT in vaccinees 
receiving single dose of the vaccine  
Proliferative response to MP antigen CD8+T cell lymphoblast response was increased at 
day 7 (1.66±1.14) compared to baseline (0.84±0.37) at day 0 after administration of 
single dose vaccine. Over the study period, the response was maximum at day 7 which 
was found gradually decreased at day 30 (0.97±0.41) and day 90 (0.73±0.37). In case of 
memory cytotoxic T-cell (CD8+/CD45RO+) lymphoblast, similar pattern of response 
were observed and the SI for CD8+/CD45RO+ T cell lymphoblast has the highest peak at 
day 7 (1.38± 1.43). After that the responses gradually wane over the period of day 30 and 
day 90. Although no significant change in SI for CD8+ T cell lymphoblast to mCT was 
observed in this group, there is a significant elevated CD8+/CD45RO+ T cell 
lymphoblast specific SI was found at day 3 and day 7. But the response did not persist at 
later stage over the period of day 30 and day 90 (Fig.3.8).  
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Figure 3.8: Comparison of lymphoblast T-cell response (blast CD8+ and CD8+ CD45RO+) to ex 
vivo stimulation of whole blood by V. cholerae  MP and mCT antigens at day 0 (before 
vaccination), day 3 (3 days after first dose of vaccination), day 7, day 30, day 90 in adult 
participants. The study days are plotted on X- axis and stimulation index on Y-axis. The response 
was expressed as Stimulation Index (SI). The response was expressed as Stimulation Index (SI). 
Each bar represents the mean value and the error bar represents the standard error of mean 
(SEM). Paired t-test was used for statistical evaluation (*P < 0.05). 
mCT 
mCT 
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3.2.3.2. CD8+ and CD8+/CD45 RO+ T-cell response to MP and mCT in double dose 
14 days apart vaccinees  
Cytotoxic and memory cytotoxic lymphoblast cell significantly increased at day 7 
(P=0.01) and day 17 (P < 0.0001) when stimulated with MP after administration of 
double dose 14 days apart vaccine. The responses of CD8+ cytotoxic T cell at day 7 
(1.16±0.36) was increased significantly and remain elevated up to day 17(1.50±0.68). 
Similar responses were observed for memory cytotoxic T cells. Response was elevated at 
day 3 and remained up to day 17 (1.12±0.49), (0.93±0.44), (1.08±0.66) respectively. No 
change in SI for CD8+ T cell lymphoblast to mCT was observed in this group; there is a 
significantly elevated CD8+/CD45RO+ T cell lymphoblast specific SI was found at day 
3, day 7 and day 17. But the response did not persist longer. (Fig.3.9). 
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Figure 3.9: Comparison of lymphoblast T-cell response (blast CD8+ and CD8+ CD45RO+) to ex 
vivo stimulation of whole blood by V. cholerae  MP and mCT antigens at day 0 (before 
vaccination), day 3 (3 days after first dose of vaccination), day 7, day 17 (3 days after second 
dose of vaccination), day 42, day 90 in adult participants. The study days are plotted on X- axis 
and stimulation index on Y-axis. The response was expressed as Stimulation Index (SI). The dot 
represents the mean SI value and the error bar represent the standard error of mean (SEM). Paired 
t-test was used for statistical evaluation (*P < 0.05). 
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3.2.3.3. CD8+ and CD8+/CD45 RO+ T-cell response to MP and  mCT in double dose 
30 days’ apart vaccinees  
Proliferative response to MP antigen, the CD8+ T cell lymphoblast specific was 
significantly increased (P=0.0006) at day 7 (1.41± 1.13) compared to baseline (0.80± 
0.52).  After administration of second dose of the vaccine, further elevation of the SI was 
found at day 33. But after that, the SI started to decline gradually although it was 
significantly elevated one month after the second dose of the vaccine (at day 60) which 
become almost comparable to baseline (0.54± 0.33) at day 90 (0.70± 0.40). 
Similar pattern of SI for MP stimulation was also observed in case of CD8+/CD45RO+ 
lymphoblast population and significantly increased response was at day 3 and remained 
elevated up to day 60 in comparison to baseline. On the contrary, no significant change in 
CD8+ T cell and CD8+/CD45RO+ T cell lymphoblast specific SI to mCT were observed 
because of the high baseline SI  to mCT in comparison to those for MP (Fig.3.10). 
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Figure 3.10: Comparison of lymphoblast T-cell response (blast CD8+ and CD8+ CD45RO+) to 
ex vivo stimulation of whole blood by V. cholerae  MP and mCT antigens at day 0 (before 
vaccination), day 3 (3 days after first dose of vaccination), day 7, day 33 (3 days after second 
dose of vaccination), day 60, day 90 in adult participants. The study days are plotted on X- axis 
and stimulation index on Y-axis. The response was expressed as Stimulation Index (SI). Each bar 
represents the mean value and the error bar represents the standard error of mean (SEM). Paired t-
test was used for statistical evaluation (*P < 0.05). 
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3.3. Vibriocidal Antibody Response  
3.3.1. Vibrio cholerae O1 Ogawa specific vibriocidal antibody response in vaccinees 
Overall 60% of single dose vaccinees, 67% of two dose 14 days apart vaccinees and 73% 
of two dose 30 days apart vaccinees responded with vibriocidal antibodies against Vibrio 
cholerae O1 Ogawa.  
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Figure 3.11: Vibriocidal antibody titer using V. cholerae O1 Ogawa as target 
bacteria in different groups receiving vaccine. The bars indicate mean reciprocal end 
titers, and error bars represent the standard errors of the mean (SEM). Asterisks indicate 
statistically significant differences between different day points (*P<0.05). The 
Wilcoxon signed-rank test and Mann Whitney test was used for analyses of the data. 
Mean fold changes and responder frequencies are also listed.  
 
The baseline mean vibriocidal  antibody titer of the single dose vaccinees was 134.6; and 
two dose (14 days and 30 days apart) vaccine cohorts were 123.7 and 82.00 , respectively 
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(Figure 3.3.1). After first dose of vaccine, all vaccine regimens showed significantly 
increased Ogawa specific vibriocidal antibody response at day 7 (single dose, P =0.002; two 
doses 14 days apart, P=0.002; two dose 30 days apart, P= 0.0007). In single dose 
regimen, this response became highly diminished within in one month of vaccination. 
However, in two doses regimen, the responses also stayed significantly higher 3 days 
after 2
nd
 dose of vaccine at day 17 (two dose 14 days apart, P=0.006) and at day 33(two 
dose 30 days apart, P=0.001). After that the response gradually went down over the 
period of day 90 in case of two doses 14 days apart vaccine regimen. On the contrary, in 
two dose 30 days apart vaccine regimen, the response was found significantly increased 
over the period of day 90 (P=0.006). However, the vibriocidal antibody response was 
also compared between day 17 and day 33 of both two dose vaccine regimens, but no 
significant difference in their response (P=0.57) was observed (Fig 3.11) 
 
3.3.2. Vibrio cholerae O1 Inaba specific vibriocidal antibody response in vaccinees 
Similar trend of vibriocidal antibody response was observed to V. cholerae O1 Inaba in 
all vaccine regimens. Overall 87% of single dose vaccinees, 80% of two dose 14 days 
apart vaccinees and 87% of two dose 30 days apart vaccinees responded with V. cholerae 
O1 Inaba specific vibriocidal antibodies. 
The baseline vibriocidal titer in single dose vaccinees was 127.7; and two dose 14 days 
apart and 30 days apart vaccines were 53.33 and 133.3 respectively (Figure 3.3.2). After 
1
st
 dose of vaccine, similar increment of V. cholerae O1 Inaba specific vibriocidal 
antibody responses were observed at day 7 in single dose (P =0.0007) and two doses 14 
days (P=0.0007) and 30 days apart (P=0.001) vaccinees. In case of two dose 14 days 
apart recipients, the response was declined 3 days after 2
nd
 dose of vaccination and it 
gradually became diminished over the study period. On the contrary, the V. cholerae O1 
Inaba specific vibriocidal antibody response was found significantly increased over the 
period of day 90 in two dose 30 days apart vaccination regimen. 
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However, comparison of the responses also between day 17 and day 33 of both double 
doses vaccination regimens was also done and significant difference in their response 
(P= 0.0077) was found (Fig.3.12). 
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Figure 3.12: Vibriocidal antibody titer using V. cholerae O1 Inaba as target bacteria in 
different groups receiving vaccine. The bars indicate mean reciprocal end titers, and error bars 
represent the standard errors of the mean (SEM). Asterisks indicate statistically significant 
differences between different day points (*P<0.05).The Wilcoxon signed-rank test and Mann–
Whitney rank sum tests were used for statistical evaluation. Mean fold changes and responder 
frequencies are also listed.   
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Immunological memory which is an important feature of adaptive immune responses 
generates specific memory cells after infection or vaccination (Megan KL MacLeod 
2010). It has been assumed that protection from cholera may be mediated by memory B 
cells capable of an anamnestic response in the gut mucosa and these memory B cells may 
depend on stimulation provided by memory T cells for their development and 
maintenance (Weil, Arifuzzaman et al. 2009). Experimental animals study has  also 
confirmed that the mucosal immune response to cholera toxin is T cell dependent and 
CD4+ helper T cells have an important role in this regard (Elson 1987) (Hirabayashi 
1991) (Holmgren 1987). Therefore, understanding the memory T cell responses is 
important for optimizing design of an oral cholera vaccine or immunization strategies.  
Previous study in Bangladeshi participants showed a satisfactory results of Shanchol as a 
promising vaccine to be safe with adequate immune responses in all ages (Saha, 
Chowdhury et al. 2011)and thus encouraged   continued  study  of this vaccine.  The 
present study was conducted to evaluate the immunogenicity of this vaccine in terms of 
adaptive immune responses. We have investigated if immunization with the oral cholera 
vaccine, Shanchol, induces cholera antigen specific CD4+ and CD8+ memory T cell 
responses in adult participants using different dose strategies. 
In a previous study, it was shown that the effector T-cells significantly increases after 6 
days of in vitro stimulation of lymphocytes (Weil, Arifuzzaman et al. 2009). Therefore 
cells are being cultured for six days to amplify the lymphoblastic T cells. To stimulate the 
T cells in vitro, V. cholerae specific immunogenic antigens, V. cholerae membrane 
preparation (MP) and G33D mutant CT (mCT) were selected. V. cholerae MP contains 
numerous of cell membrane proteins, outer membrane protein U precursor porin (OMPU) 
most abundantly. Although Shanchol does not contain any detectable cholera toxin (CT), 
proliferative responses to the mCT has been evaluated in this study as it has been done 
earlier with Dukoral, another oral cholera vaccine. Although CT is a potent mucosal-
vaccine adjuvant in experimental animals (Northrup and Fauci 1972) (Elson and Ealding 
1984) (Freytag and Clements 2005), it is already hypothesized that anti-CT immunity is 
not sufficient or even necessary for protection from cholera (Apter, Lencer et al. 1993) 
(Bishop, Tarique et al.). Only DMEM complete medium has been used as control and 
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Phytohaemagglutinin (PHA), a known polyclonal activator was used as positive 
stimulatory antigens that helped to ensure the proliferation of lymphocytes in the in vitro 
culture. 
To assess T-cell memory, flow cytometric analysis was used to detect CD45RO+ T cells 
which is a well established marker for T-cell memory (Ahmed and Gray 1996) (Sprent 
and Surh 2002). FASCIA technique was employed rather than other currently available 
methods as it only requires small amounts of blood. 
 
In this study, Shanchol vaccine was administered using different dose patterns as single 
dose, double dose 14 days apart and double dose 30 days apart. It was observed that there 
is a gradual increase in CD4+ T cell and CD8+ T cell response to MP which become 
significantly maximum at day 7 after administration of one dose of the vaccine in all 
groups. Similar proliferative response was found for CD4+/CD45RO+ and 
CD8+/CD45RO+ memory T-cell response to V. cholerae MP. In a previous study, 
increased proliferative memory T cell response to V. cholerae antigens MP, TcpA, VCC 
was observed at day 7 in adult patients due to exposure to V. cholerae (Weil, 
Arifuzzaman et al. 2009). It is hypothesized that early T cell responses is required for 
generation and maintenance of subsequent durable memory B cell responses (Weil, 
Arifuzzaman et al. 2009). So, we assume that the significantly elevated memory T cell 
responses observed by day 7 after vaccination, a time prior to and concurrent with the 
development of B cell responses, may play a major role in development of memory B cell 
response to this vaccine. 
In the present two dose vaccination strategies, significantly proliferative 
CD4+/CD45RO+ and CD8+/CD45RO+  memory T-cell responses to V. cholerae MP 
have also been observed 3 days after second dose of vaccination (at day 17 and day 33) 
which was found to be  absent in one dose of vaccination regimen. This can happen for 
the re-exposure of the vaccinees in two dose vaccination scheme that causes immediate 
proliferative response. 
Although in a previous study, significant T-cell responses were observed to mCT in 
young children after administration of Dukoral vaccine (Ahmed, Arifuzzaman et al. 
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2009), no such significantly elevation of  memory T cell responsiveness could  be 
detected to mCT in adult participants after Shanchol vaccination. It is assumed that the 
response to mCT is absent as the vaccine contains LPS of different V. cholerae strains 
and an undetectable level of CTB. 
However, a high baseline response to mCT has been found in all vaccinee groups of this 
study. Similarly, high baseline responses to mCT were found even in children after 
administration of Dukoral vaccine in a previous study (Ahmed, Arifuzzaman et al. 2009). 
Previous priming of study participants living in areas of endimicity with V. cholerae, E. 
coli can be responsible for this as the ETEC strains express the heat labile toxin (LT) 
which is highly homologous with cholera toxin (CT) and is responsible for the non-
specific responses (Ahmed, Arifuzzaman et al. 2009). 
In the present  study, within one month of vaccine administration, the proliferative 
CD4+/CD45RO+ memory T-cell response gradually wanes down causing no significant 
response after one month of intake of last vaccine dose in all vaccination schemes and at 
day 90 the proliferative response was found highly diminished. This correlates with 
earlier findings where it was explained that protective immunity generated by vaccine 
candidates is partial and short-lived which declines more quickly in people living in 
Cholera endemic zone in contrast to natural infection (Weil, Arifuzzaman et al. 2009). 
Vibriocidal antibody assay is a surrogate marker that is widely used to evaluate the 
efficacy of cholera vaccine (Saha D 2004). This in vitro assay has been shown to 
correlate with protective immunity to oral cholera vaccine (Clemens 1987) and there is 
no threshold at which protection is complete (Saha D 2004).  
In our study, the V. cholerae O1 Ogawa and Inaba specific vibriocidal antibody responses 
were found maximum at day 7 after administration of one dose of vaccine in all vaccine 
cohorts. After one month of last dose of the vaccination, the responses declined gradually 
and it was found highly diminished over the period of day 90 in all vaccination regimens 
except for the double dose 30 days apart vaccination regimen where the responses were 
found lower but significantly increased in comparison to baseline. This correlates with 
previous findings where it was shown that the titer falls to baseline within several months 
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after natural infection (Harris, Bhuiyan et al. 2009). So, it can be suggested that similar to 
natural infection with V. cholerae, the long-term immunity following vaccination may be 
mediated through memory and anamnestic responses (Alam, Riyadh et al.). 
This study shows that the memory T cell response is important in cholera and also 
provides a tool to understand the effectiveness of vaccine. This study may help to 
understand how this new vaccines may need to be modified to elicit an immune response 
that will provide long-lasting protection. The findings of this study may also explain that 
the relatively short-term protection is afforded by administration of Shanchol oral cholera 
vaccines. 
As it is found in our study that the vaccine is safe, immunogenic and effective following 
a single-dose; it will have intense implications in case of emergencies where a double 
dose regimen is difficult to set up. The delivery system and uptake of the vaccine is also 
feasible and other associated public health costs of immunization is minimized when the 
single dose vaccination is available. Thus, the findings of this study imply that the single 
dose may be as effective as double dose (given 14 days apart and 30 days apart).  
From the present study it may be concluded that 
i. Early proliferative T cell response is a potent tool that provides help for the generation 
of subsequent memory B cell responses. 
ii. The long-term immunity following vaccination may be mediated through memory and 
anamnestic responses. 
iii. Early T-cell-mediated events would help to design a more effective vaccine and single 
dose vaccine is as effective as double doses. 
Recommendation for future work 
As this study has been carried out in small number of participants, further study with a 
large sample size should be conducted to confirm robust efficacy and durability 
of Shanchol single dose vaccine and to conclude that single dose is as effective as the two 
dose regimen of vaccination in cholera endemic areas like Bangladesh. 
  
 
 
 
 
 
 
Chapter 5  
                                               References              
 
 
 
 
 
 
 Chapter Five: References                                                                                                           66 
 
1. Abbas , L. (2010). Basic Immunology  
2. Abul K. Abbas, A. H. L., Shiv Pillal. (2007). "Cellular and Molecular 
Immunology". 
3. Ahmed, R. and D. Gray (1996). "Immunological memory and protective 
immunity: understanding their relation." Science 272(5258): 54-60. 
4. Ahmed, T., M. Arifuzzaman, et al. (2009). "CD4+ T-cell responses to an oral 
inactivated cholera vaccine in young children in a cholera endemic country and 
the enhancing effect of zinc supplementation." Vaccine 28(2): 422-9. 
5. Akbar, A. N., L. Terry, et al. (1988). "Loss of CD45R and gain of UCHL1 
reactivity is a feature of primed T cells." J Immunol 140(7): 2171-8. 
6. Alam, M. M., M. A. Riyadh, et al. "Antigen-specific memory B-cell responses in 
Bangladeshi adults after one- or two-dose oral killed cholera vaccination and 
comparison with responses in patients with naturally acquired cholera." Clin 
Vaccine Immunol 18(5): 844-50. 
7. Alberts B, J. A., Lewis J, Raff M, Roberts k, Walter P (2002). Molecular Biology 
of the Cell. New York, Garland Science:, . 
8. Anderson, P. (2008). "Post-transcriptional control of cytokine production." Nat 
Immunol 9(4): 353-9. 
9. Angelichio, M. J., J. Spector, et al. (1999). "Vibrio cholerae intestinal population 
dynamics in the suckling mouse model of infection." Infect Immun 67(8): 3733-9. 
10. Anh, D. D., G. Canh do, et al. (2007). "Safety and immunogenicity of a 
reformulated Vietnamese bivalent killed, whole-cell, oral cholera vaccine in 
adults." Vaccine 25(6): 1149-55. 
11. Apter, F. M., W. I. Lencer, et al. (1993). "Monoclonal immunoglobulin A 
antibodies directed against cholera toxin prevent the toxin-induced chloride 
secretory response and block toxin binding to intestinal epithelial cells in vitro." 
Infect Immun 61(12): 5271-8. 
12. Asaduzzaman, M., E. T. Ryan, et al. (2004). "The major subunit of the toxin-
coregulated pilus TcpA induces mucosal and systemic immunoglobulin A 
immune responses in patients with cholera caused by Vibrio cholerae O1 and 
O139." Infect Immun 72(8): 4448-54. 
 Chapter Five: References                                                                                                           67 
 
13. Attridge, S. R., A. Fazeli, et al. (2001). "Isolation and characterization of 
bacteriophage-resistant mutants of Vibrio cholerae O139." Microb Pathog 30(4): 
237-46. 
14. bacteriology, T. b. o. Antigenic Variation and LPS Structure in Vibrio cholerae. 
(www.textbookofbacteriology.net/cholera.html). 
15. Baumann, P. (1984). Bergey’s manual of systematic bacteriology,, Williams & 
Wilkins, Baltimore. 
16. Bell, E. B. and J. Westermann (2008). "CD4 memory T cells on trial: 
immunological memory without a memory T cell." Trends Immunol 29(9): 405-
11. 
17. Bhuiyan, T. R., S. B. Lundin, et al. 
18. Bhuiyan, T. R., S. B. Lundin, et al. (2009). "Cholera caused by Vibrio cholerae 
O1 induces T-cell responses in the circulation." Infect Immun 77(5): 1888-93. 
19. Bishop, A. L., Camilli, A. (2011). "Vibrio cholerae: lessons for mucosal vaccine 
design." Expert Rev Vaccines 10(1): 79-94. 
20. Bishop, A. L., A. A. Tarique, et al. "Immunization of mice with vibrio cholerae 
outer-membrane vesicles protects against hyperinfectious challenge and blocks 
transmission." J Infect Dis 205(3): 412-21. 
21. Black, R. E. (1982). "The prophylaxis and therapy of secretory diarrhea." Med 
Clin North Am 66(3): 611-21. 
22. Bradford A. Kay, C. A., Bopp, Joy G. Wells.. Isolation and identification of 
Vibrio cholerae O1 from fecal specimens. 
23. Brandtzaeg, P., K. Kett, et al (1986). "Distribution of mucosal IgA and IgG 
subclass-producing immunocytes and alterations in various disorders."" Monogr 
Allergy 20: 179-94. 
24. Buus, S. (1999). "Description and prediction of peptide-MHC binding: the 'human 
MHC project'." Curr Opin Immunol 11(2): 209-13. 
25. Cabrera, O., M. E. Martinez, et al. (2006). "Preparation and evaluation of vibrio 
cholerae O1 EL Tor Ogawa lipopolysaccharide-tetanus toxoid conjugates." 
Vaccine 24 Suppl 2: S2-74-5. 
 Chapter Five: References                                                                                                           68 
 
26. Cash, R. A., S. I. Music, et al. (1974). "Response of man to infection with Vibrio 
cholerae. II. Protection from illness afforded by previous disease and vaccine." J 
Infect Dis 130(4): 325-33. 
27. Chandran, P., S. Satthaporn, et al. (2003). "Inflammatory bowel disease: 
dysfunction of GALT and gut bacterial flora (II)." Surgeon 1(3): 125-36. 
28. Cheroutre, H. and L. Madakamutil (2004). "Acquired and natural memory T cells 
join forces at the mucosal front line." Nat Rev Immunol 4(4): 290-300. 
29. Chiang, S. L. and J. J. Mekalanos (1999). "rfb mutations in Vibrio cholerae do not 
affect surface production of toxin-coregulated pili but still inhibit intestinal 
colonization." Infect Immun 67(2): 976-80. 
30. Clemens, J. D., D. A. Sack, et al. (1986). "Field trial of oral cholera vaccines in 
Bangladesh." Lancet 2(8499): 124-7. 
31. Clemens, J. D., D. A. Sack, et al. (1990). "Field trial of oral cholera vaccines in 
Bangladesh: results from three-year follow-up." Lancet 335(8684): 270-3. 
32. Clemens, J. D., Stanton, B.F., Chakraborty, J., Sack, D.A., Khan, M.R., Huda, S., 
Ahmed, F.,Harris, J.R., Yunus, M., Khan, M.U., et al. (1987). "B subunit-whole 
cell and whole cellonly oral vaccines against cholera: studies on reactogenicity 
and immunogenicity." J. Infect. Dis. 155 
33. Colwell, R. R. (1996). "Global climate and infectious disease: the cholera 
paradigm." Science 274(5295): 2025-31. 
34. Control, C. f. D. (2013). "Laboratory Methods for the Diagnosis of Vibrio 
cholerae"." Centre for Disease Control. 
35. De Groot, A. S., M. Ardito, et al. (2009). "Immunoinformatic comparison of T-
cell epitopes contained in novel swine-origin influenza A (H1N1) virus with 
epitopes in 2008-2009 conventional influenza vaccine." Vaccine 27(42): 5740-7. 
36. Deen, J. L., L. von Seidlein, et al. (2008). "The high burden of cholera in children: 
comparison of incidence from endemic areas in Asia and Africa." PLoS Negl 
Trop Dis 2(2): e173. 
37. Doolan, D. L., S. Southwood, et al. (2003). "Identification of Plasmodium 
falciparum antigens by antigenic analysis of genomic and proteomic data." Proc 
Natl Acad Sci U S A 100(17): 9952-7. 
 Chapter Five: References                                                                                                           69 
 
38. Dranoff, G. (2004). "Cytokines in cancer pathogenesis and cancer therapy." 
Nature Reviews Cancer 4: 11-22  
39. Elson, C. O. and W. Ealding (1984). "Cholera toxin feeding did not induce oral 
tolerance in mice and abrogated oral tolerance to an unrelated protein antigen." J 
Immunol 133(6): 2892-7. 
40. Elson, C. O. a. W. E. (1987). ""Ir gene control of the murine secretory IgA 
response to cholera toxin." " Eur J Immunol 17(3) 17(3): 425-8. 
41. Faruque, S. M., G. B. Nair, et al. (2004). "Genetics of stress adaptation and 
virulence in toxigenic Vibrio cholerae." DNA Cell Biol 23(11): 723-41. 
42. Finkelstein, R. (1962). "Vibriocidal antibody inhibition (VAI) analysis: a 
technique for the identification of the predominant vibriocidal antibodies in serum 
and for the detection of Vibrio cholerae antigens." J Immunol ( 89): 264-71. 
43. Finkelstein, R. A. (1996). "Cholera, Vibrio cholerae O1 and O139, and Other 
Pathogenic Vibrios." 
44. Flach, C. F., F. Qadri, et al. (2007). "Broad up-regulation of innate defense factors 
during acute cholera." Infect Immun 75(5): 2343-50. 
45. Freytag, L. C. and J. D. Clements (2005). "Mucosal adjuvants." Vaccine 23(15): 
1804-13. 
46. Glass, R. I., S. Becker, et al. (1982). "Endemic cholera in rural Bangladesh, 1966-
1980." Am J Epidemiol 116(6): 959-70. 
47. Gutcher, I. and B. Becher (2007). "APC-derived cytokines and T cell polarization 
in autoimmune inflammation." J Clin Invest 117(5): 1119-27. 
48. Harris, A. M., M. S. Bhuiyan, et al. (2009). "Antigen-specific memory B-cell 
responses to Vibrio cholerae O1 infection in Bangladesh." Infect Immun 77(9): 
3850-6. 
49. Harris, J. B., LaRocque, R. C.,Qadri, F.,Ryan, E. T.,Calderwood, S. B. (2012). 
"Cholera." Lancet 379(9835): 2466-76. 
50. Harris, J. B., R. C. LaRocque, et al. (2008). ""Susceptibility to Vibrio cholerae 
infection in a cohort of household contacts of patients with cholera in 
Bangladesh." " PLoS Negl Trop Dis 2(4)e221. 
 Chapter Five: References                                                                                                           70 
 
51. Heidelberg, J. F., J. A. Eisen, et al. (2000). "DNA sequence of both chromosomes 
of the cholera pathogen Vibrio cholerae." Nature 406(6795): 477-83. 
52. Herrington, D. A., Hall, R. H., Losonsky, G., Mekalanos, J. J., Taylor, R. K., and 
Levine, M. M. (1988). "Toxin, toxin-coregulated pili, and the toxR regulon are 
essential for Vibrio cholerae pathogenesis in humans." J Exp Med 168: 1487-
1492. 
53. Hirabayashi, Y., S. I. Tamura, et al. (1991). ""H-2-unrestricted adjuvant effect of 
cholera toxin B subunit on murine antibody responses to influenza virus 
haemagglutinin."" Immunology 72(3): 329-35. 
54. Hirabayashi, Y., S. I. Tamura, et al. 
55. Holmgren, J. and C. Czerkinsky (2005). "Mucosal immunity and vaccines." Nat 
Med 11(4 Suppl): S45-53. 
56. Holmgren, J., A. M. Svennerholm, et al. 
57. Holmgren, J. a. A. M. S. (1987). ""Mechanisms of disease and immunity in 
cholera: a review." " J Infect Dis 136 Suppl: S: 105-12. 
58. Homann, D., L. Teyton, et al. (2001). "Differential regulation of antiviral T-cell 
immunity results in stable CD8+ but declining CD4+ T-cell memory." Nat Med 
7(8): 913-9. 
59. Hou, S., L. Hyland, et al. (1994). "Virus-specific CD8+ T-cell memory 
determined by clonal burst size." Nature 369(6482): 652-4. 
60. Iredell, J. R., U. H. Stroeher, et al. (1998). "Lipopolysaccharide O-antigen 
expression and the effect of its absence on virulence in rfb mutants of Vibrio 
cholerae O1." FEMS Immunol Med Microbiol 20(1): 45-54. 
61. Iwanaga, M. and K. Yamamoto (1985). "New medium for the production of 
cholera toxin by Vibrio cholerae O1 biotype El Tor." J Clin Microbiol 22(3): 405-
8. 
62. Jertborn, M., A. M. Svennerholm, et al. (1984). ""Gut mucosal, salivary and 
serum antitoxic and antibacterial antibody responses in Swedes after oral 
immunization with B subunit-whole cell cholera vaccine."" Int Arch Allergy Appl 
Immunol 75(1) 38-43. 
 Chapter Five: References                                                                                                           71 
 
63. Jobling, M. G. and R. K. Holmes (1991). "Analysis of structure and function of 
the B subunit of cholera toxin by the use of site-directed mutagenesis." Mol 
Microbiol 5(7): 1755-67. 
64. John D. Clemens, S. S., Binod K. Sah,David A. Sack (2014). cholera vaccines. 
Vaccines, Elsevier Inc. 
65. Kaper, J., Alessio Fasano, and Michele Trucksis. (1994). "Toxins of Vibrio 
cholerae”. Vibrio cholerae and cholera: Molecular to global perspectives." 145-
168. 
66. Kelsall BL, S. W., Mosby (1996). "Clinical immunology. Principles and 
practice." 
67. Kenner JR, C. T., Taylor DN, Trofa AF, Oro M, Barrera T, et al. (1995). "Peru-
15, an improved live attenuated oral vaccine candidate for the Vibrio cholerae 
O1." J Infect Dis 172: 1126-9. 
68. Kenneth Todar, P. (2012). "Web Review of Todar's Online Textbook of 
Bacteriology Vibrio cholerae and Asiatic Cholera ". 
69. Khan, A. M., M. S. Hossain, et al. (2009). "Bacterial enteropathogens of neonates 
admitted to an urban diarrhoeal hospital in Bangladesh." J Trop Pediatr 55(2): 
122-4. 
70. Khan, M. K., S. Zaman, et al. (2014). "In silico predicted mycobacterial epitope 
elicits in vitro T-cell responses." Mol Immunol 61(1): 16-22. 
71. Koelle, K., X. Rodo, et al. (2005). "Refractory periods and climate forcing in 
cholera dynamics." Nature 436(7051): 696-700. 
72. Kovach, M. E., M. D. Shaffer, and K. M. Peterson. (1996). "A putative integrase 
gene defines the distal end of a large cluster of toxr-regulated colonization genes 
in Vibrio cholerae." Microbiology 142 ( Pt 8): 2165-74. 
73. Kuchta, A., T. Rahman, et al. (2011). "Vibrio cholerae O1 infection induces 
proinflammatory CD4+ T-cell responses in blood and intestinal mucosa of 
infected humans." Clin Vaccine Immunol 18(8): 1371-7. 
74. Lauemoller, S. L., C. Kesmir, et al. (2000). "Identifying cytotoxic T cell epitopes 
from genomic and proteomic information: "The human MHC project."" Rev 
Immunogenet 2(4): 477-91. 
 Chapter Five: References                                                                                                           72 
 
75. Lee, S. H., Hava, D. L., Waldor, M. K., and Camilli, A. (1999). "Regulation and 
temporal expression patterns of Vibrio cholerae virulence genes during infection. 
." Cell 99: 625-634. 
76. Levine, M. M., R. E. Black, et al. (1981). "Duration of infection-derived 
immunity to cholera." J Infect Dis 143(6): 818-20. 
77. Levine, M. M., D. R. Nalin, et al. (1979). "Immunity of cholera in man: relative 
role of antibacterial versus antitoxic immunity." Trans R Soc Trop Med Hyg 
73(1): 73(1): 3-9. 
78. Levine, M. M. and J. B. Kaper (1993). "Live oral vaccines against cholera: an 
update." Vaccine 11(2): 207-12. 
79. Longini, I. M., Jr., A. Nizam, et al. (2007). "Controlling endemic cholera with 
oral vaccines." PLoS Med 4(11): e336. 
80. MacLeod, M. K., E. T. Clambey, et al. (2009). ""CD4 memory T cells: what are 
they and what can they do?"" Semin Immunol 21(2): 53-61. 
81. Mahalanabis, D., A. L. Lopez, et al. (2008). "A randomized, placebo-controlled 
trial of the bivalent killed, whole-cell, oral cholera vaccine in adults and children 
in a cholera endemic area in Kolkata, India." PLoS One 3(6): e2323. 
82. Male, D. e. (2006). Immunology. UK, Elsevier. 
83. Mathan, M. M., G. Chandy, et al. (1995). "Ultrastructural changes in the upper 
small intestinal mucosa in patients with cholera." Gastroenterology 109(2): 422-
30. 
84. Megan KL MacLeod, J. W. K., and Philippa Marrack (2010). "Memory CD4 T 
cells: generation, reactivation and re-assignment." Immunology. May 2010; : 
130(1): 10–15. 
85. Morris, J. G., Jr. (2003). "Cholera and other types of vibriosis: a story of human 
pandemics and oysters on the half shell." Clin Infect Dis 37(2): 272-80. 
86. Nelson, E. J., J. B. Harris, et al. (2009). "Cholera transmission: the host, pathogen 
and bacteriophage dynamic." Nat Rev Microbiol 7(10): 693-702. 
87. Nelson EJ, N. D., Salam MA, Sack DA (2011). "Antibiotics for both moderate 
and severe cholera." N Engl J Med. 364(1):5-7.  . 
 Chapter Five: References                                                                                                           73 
 
88. Nesper, J., C. M. Lauriano, et al. (2001). "Characterization of Vibrio cholerae O1 
El tor galU and galE mutants: influence on lipopolysaccharide structure, 
colonization, and biofilm formation." Infect Immun 69(1): 435-45. 
89. Northrup, R. S. and A. S. Fauci (1972). "Adjuvant effect of cholera enterotoxin on 
the immune response of the mouse to sheep red blood cells." J Infect Dis 125(6): 
672-3. 
90. Parkin, J. and B. Cohen (2001). "An overview of the immune system." Lancet 
357(9270): 1777-89. 
91. Parment, P. A., A. Svahn, et al. (2003). "Immunogenicity and reactogenicity of a 
single dose of live attenuated varicella vaccine and a booster dose of measles-
mumps-rubella vaccine given concomitantly at 12 years of age." Scand J Infect 
Dis 35(10): 736-42. 
92. Pazzani, C., M. Scrascia, et al. (2006). "Molecular epidemiology and origin of 
cholera reemergence in Italy and Albania in the 1990s." Res Microbiol 157(6): 
508-12. 
93. Provenzano D, K. P., Wade WF.. (2006). "The ABCs (antibody, B cells, and 
carbohydrate epitopes) of cholera immunity: considerations for an improved 
vaccine. ." Microbiol. Immunol. 50: 899–927. 
94. Qadri, F., F. Ahmed, et al. (1999). "Lipopolysaccharide- and cholera toxin-
specific subclass distribution of B-cell responses in cholera." Clin Diagn Lab 
Immunol 6(6): 812-8. 
95. Qadri, F., T. R. Bhuiyan, et al. (2004). "Acute dehydrating disease caused by 
Vibrio cholerae serogroups O1 and O139 induce increases in innate cells and 
inflammatory mediators at the mucosal surface of the gut." Gut 53(1): 62-9. 
96. Qadri F, e. a. (1997). "Comparison of immune responses in patients infected 
withVibrio choleraeO139 and O1." Infect. Immun.64: 3571–3576. 
97. Qadri, F., G. Jonson, et al. (1997). "Immune response to the mannose-sensitive 
hemagglutinin in patients with cholera due to Vibrio cholerae O1 and O0139." 
Clin Diagn Lab Immunol 4(4): 429-34. 
98. Qadri, F., G. Mohi, et al. 
 Chapter Five: References                                                                                                           74 
 
99. Qadri, F., G. Mohi, et al. (1995). "Comparison of the vibriocidal antibody 
response in cholera due to Vibrio cholerae O139 Bengal with the response in 
cholera due to Vibrio cholerae O1." Clin Diagn Lab Immunol 2(6): 685-8. 
100. Qadri, F., R. Raqib, et al. (2002). "Increased levels of inflammatory mediators in 
children and adults infected with Vibrio cholerae O1 and O139." Clin Diagn Lab 
Immunol 9(2): 221-9. 
101. R. W. Dutton, L. M. B., and S. L. Swain (1998). "T CELL MEMORY." Annu. 
Rev. Immunol 16:: 201–23. 
102. Richard A. Goldsby, T. J. K., Barbara A. Osborne, Janis Kuby . (2006). 
Immunology. 
103. Richie, E. E., N. H. Punjabi, et al. (2000). "Efficacy trial of single-dose live oral 
cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic 
area." Vaccine 18(22): 2399-410. 
104. Roitt Ivan , D. P. (2001). Roitt's Essential Immunology. 
105. Sack, D. A., R. B. Sack, et al. (2004). "Cholera." Lancet 363(9404): 223-33. 
106. Saha, A., M. I. Chowdhury, et al. (2011). "Safety and immunogenicity study of a 
killed bivalent (O1 and O139) whole-cell oral cholera vaccine Shanchol, in 
Bangladeshi adults and children as young as 1 year of age." Vaccine 29(46): 
8285-92. 
107. Saha D, L. R., Khan AI, Harris JB, Begum YA,Akramuzzaman SM, Faruque 
AS, Ryan ET, Qadri F,Calderwood SB (2004). " Incomplete correlation of serum 
vibriocidal antibody titer with protection fromVibrio cholerae infection in urban 
Bangladesh." J Infect Dis 189: 2318–2322. 
108. Sallusto, F., A. Lanzavecchia, et al. (2010). "From vaccines to memory and 
back." Immunity 33(4): 451-63. 
109. Sallusto, F., D. Lenig, et al. (1999). "Two subsets of memory T lymphocytes 
with distinct homing potentials and effector functions." Nature 401(6754): 708-
12. 
110. Sanchez, J. and J. Holmgren (1989). "Recombinant system for overexpression of 
cholera toxin B subunit in Vibrio cholerae as a basis for vaccine development." 
Proc Natl Acad Sci U S A 86(2): 481-5. 
 Chapter Five: References                                                                                                           75 
 
111. Sanchez, J. and J. Holmgren (2011). "Cholera toxin - a foe & a friend." Indian J 
Med Res 133: 153-63. 
112. Sanchez, J. L., B. Vasquez, et al. (1994). "Protective efficacy of oral whole-
cell/recombinant-B-subunit cholera vaccine in Peruvian military recruits." Lancet 
344(8932): 1273-6. 
113. Sanofi (2009). "Shantha Press Release Shantha Introduces Shanchol™ India's 
1st Oral Cholerae Vaccine." 
114. Seddon, B., P. Tomlinson, et al. (2003). "Interleukin 7 and T cell receptor 
signals regulate homeostasis of CD4 memory cells." Nat Immunol 4(7): 680-6. 
115. Shamini, G., M. Ravichandran, et al. "Structural inferences for Cholera toxin 
mutations in Vibrio cholerae." Bioinformation 6(1): 1-9. 
116. Shantha, B. (2011). Shanchol. http://www.shanthabiotech.com/. 
117. Sinclair, D., K. Abba, et al. (2011). "Oral vaccines for preventing cholera." 
Cochrane Database Syst Rev(3): CD008603. 
118. Snyder JD, A. D., Levine MM, et al.  (1981). "Serological studies of normally 
acquired infection with Vibrio cholerae serogroup O1 in the United States." 
Journal of Infectious Dis 143:: 182-7. 
119. Sprent, J. and C. D. Surh (2002). "T cell memory." Annu Rev Immunol 20: 551-
79. 
120. Springer, T. A. (1994). "Traffic signals for lymphocyte recirculation and 
leukocyte emigration: the multistep paradigm." Cell 76(2): 301-14. 
121. Stoll, B. J., Glass, R. I., Huq, M. I., Khan, M. U., Holt, J. E., and Banu, H. 
(1982). "Surveillance of patients attending a diarrhoeal disease hospital in 
Bangladesh." Br Med J (Clin Res Ed) , 285: 1185-1188. 
122. Sur D, K. S., Sah B, Manna B, Ali M, Paisley AM, Niyogi SK, Park JK, Sarkar 
B, Puri MK, Kim DR, Deen JL, Holmgren J, Carbis R, Rao R, Nguyen TV, Han 
SH, Attridge S, Donner A, Ganguly NK, Bhattacharya SK, Nair GB, Clemens 
JD, Lopez AL. (2011 ). "Efficacy of a low-cost, inactivated whole-cell oral 
cholera vaccine: results from 3 years of follow-up of a randomized, controlled 
trial." PLoS Negl Trop Dis. 2011 Oct;5(10):e1289.  
 Chapter Five: References                                                                                                           76 
 
123. Sur, D., A. L. Lopez, et al. (2009). "Efficacy and safety of a modified killed-
whole-cell oral cholera vaccine in India: an interim analysis of a cluster-
randomised, double-blind, placebo-controlled trial." Lancet 374(9702): 1694-
702. 
124. Svennerholm, A. M., M. Jertborn, et al. (1984). "Mucosal antitoxic and 
antibacterial immunity after cholera disease and after immunization with a 
combined B subunit-whole cell vaccine." J Infect Dis 149(6): 884-93. 
125. Tacket CO, C. M., Wasserman SS, Losonsky G, Livio S,Kotloff K, Edelman R, 
Kaper JB, Cryz SJ, Giannella RA, Schiff and L. M. G (1999). "Randomized, 
double-blind, placebocontrolled, multicentered trialof the efficacy of a single 
dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following 
challenge withVibrio choleraeO1 El tor inaba three months after vaccination." 
Infect Immun 67(6341–6345.). 
126. Terabe, M. and J. A. Berzofsky (2008). "The role of NKT cells in tumor 
immunity." Adv Cancer Res 101: 277-348. 
127. Thomas J. Kindt, B. A. O., Richard A. Goldsby (2000). Kuby Immunology. 
128. Times, T. N. Y. (2010). Haiti’s Latest Misery. 
129. van Leeuwen, E. M., J. Sprent, et al. (2009). "Generation and maintenance of 
memory CD4(+) T Cells." Curr Opin Immunol 21(2): 167-72. 
130. Varga, S. M. and R. M. Welsh (1998). "Stability of virus-specific CD4+ T cell 
frequencies from acute infection into long term memory." J Immunol 161(1): 
367-74. 
131. Waldor, M. K., R. Colwell, et al. (1994). "The Vibrio cholerae O139 serogroup 
antigen includes an O-antigen capsule and lipopolysaccharide virulence 
determinants." Proc Natl Acad Sci U S A 91(24): 11388-92. 
132. Ward, D. E. (2014). Tonsils Make T-Cells, Too, Ohio State Study Shows. 
U.S.A, Ohio State University. 
133. Weil, A. A., M. Arifuzzaman, et al. (2009). "Memory T-cell responses to Vibrio 
cholerae O1 infection." Infect Immun 77(11): 5090-6. 
134. Weil, A. A., A. I. Khan, et al. (2009). "Clinical outcomes in household contacts 
of patients with cholera in Bangladesh." Clin Infect Dis 49(10): 1473-9. 
 Chapter Five: References                                                                                                           77 
 
135.WHO (2009). Initiative for vaccine research. 
136. WHO (2010). "Cholera vaccines: WHO position paper." Wkly. Epidemiol. 
Rec.85: 117–128. 
137. WHO ( 2012). Cholera Fact sheet N°107. 
138. Willinger, T., T. Freeman, et al. (2005). "Molecular signatures distinguish 
human central memory from effector memory CD8 T cell subsets." J Immunol 
175(9): 5895-903. 
139. Wolf, A. A., M. G. Jobling, et al. (2008). "Attenuated endocytosis and toxicity 
of a mutant cholera toxin with decreased ability to cluster ganglioside GM1 
molecules." Infect Immun 76(4): 1476-84. 
140. Zaph, C., K. A. Rook, et al. (2006). "Persistence and function of central and 
effector memory CD4+ T cells following infection with a gastrointestinal 
helminth." J Immunol 177(1): 511-8. 
141. Zhang, R. G., D. L. Scott, et al. (1995). "The three-dimensional crystal structure 
of cholera toxin." J Mol Biol 251(4): 563-73. 
142. Zuckerman, J. N., L. Rombo, et al. (2007). "The true burden and risk of cholera: 
implications for prevention and control." Lancet Infect Dis 7(8): 521-30. 
 
 
  
 
 
 
 
                               Appendices 
 
 Appendices                                                                                                                                  i 
 
APPENDIX A 
Laboratory Apparatus 
1. Fluorescent-activated cell sorter (FACSCalibur, Becton Dickinson, San Jose, CA) 
2. Mini scale centrifugations were carried out in a Sorvall® pico microfuge and 
large-scale centrifugation were carried out in a Sorvall
®
 Legend
™
 XRT super 
speed centrifuge.   
3. ELISA reader (ASCENT Multiskan® reader.) 
4. Spectrophotometer- BECKMAN COULTERTM 
5. Water Bath 
6. Incubator Thermo Scientific 
7. Eppendorf tubes and micropipette tips were taken from Eppendorf® and Sigma, 
and were sterilized by autoclaving at 121°C for 20 minutes.  
8. Petri dishes used in the experiments were provided by either Sterilin or Gibco. 
Screw capped tubes and other glass wares were taken from Pyrex
® 
Labware, USA.  
9. Plastic tubes and pipettes were of Falcon®; both were the brands of Becton, 
Dickinson and Company, BD. 
10. 96-well ELISA plates were obtained from  Nunc™, Sweden 
11. Polystyrene FACS tubes (Becton Dickinson, San Jose, USA) 
12. Micropipettes were from Thermo Labsystems, Denmark. 
13. Multi-channel dispenser (Lab System, USA) 
14. Microtiter plates (Nunc, Roskilde, Denmark) 
15. BD Falcon™ round-bottom tubes 
16. Filter- Minisart® Sartorius stedim biotech, Germany. 
17. Aluminum foil 
18. Paraffin paper (BEMIS® Neenah WI, U.S.A) 
19. Heparin-coated sterile vacutainer tubes (Becton Dickinson, Ruther-ford, NJ) 
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Chemicals/Reagents 
1. FBS (Fetal Bovine Serum Albumin), Gibco BRL- 16140-071 
2. H2O2 (Hydrogen Peroxide), Fisher Scientific, H-325 
3. MgCl2 (Magnesium chloride), Sigma- 7786-30-3 
4. Na-acetate, Sigma-127-09-3 
5. NaHCO3 (Sodium bi-carbonate), Fisher Scientific- S233-500 
6. EDTA (TitriplexR II Merck 1.0841) 
7. Sodium azide, NaN3 
8. BD Stabilizing Fixative 
9. Guinea pig complement 
10. Dulbecco Modified Eagle Medium, DMEM (Invitrogen, USA) 
11. FACS flow  (Becton Dickinson) 
12. FACS antibody : 
1. Anti-CD3 APC (Becton Dickinson) 
2. Anti-CD4 PerCP (Becton Dickinson) 
3. Anti-CD8 FITC (Becton Dickinson) 
4. Anti-CD45RO PE (eBioscience) 
13. Antigen used in FASCIA method: 
1. G33D mutant holotoxin (mutant form of cholera toxin) 
2. MP (Cholerae membrane protein) 
3. PHA (Phytohemagglutinin) 
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APPENDIX B 
1. Preparation of phosphate buffered saline (PBS) (Vacutainer System; Becton 
Dickinson, Rutherford, NJ) (P
H
   between 7.2 to 7.4) 
Reagents             Amount 
NaCl (0.136mM Fischer Scientific, Pittsburgh, PA, 
U.S.A ) 
             80.00 gm 
Na2HPO4              27.50 gm 
KH2PO4                2.75 gm 
KCL (Fischer Scientific, Pittsburgh, PA, USA)                2.00 gm 
Deionized water               1000 mL 
The concentrated solution (10xPBS) was diluted ten times and was used as working 
solution. 
3. Preparation of FACS Buffer (1000 mL) (P
H 
between 7.2-7.4)        
      No heating (P
H    
between 7.2-7.4) 
Sterilization should be done by filtration, not autoclaved. 
Kept for 3 months  
Store at 2-8
° 
C 
4. Preparation of Normal Saline 
Reagent Amount 
Distilled Water     1L 
Sodium Chloride ( NaCl )     9gm 
Reagents              Amounts 
EDTA  (Titriplex
R
 II Merck 1.0841)                 0.375 gm 
Albumin (Bovine serum albumin)                     2.0 gm 
Sodium azide, NaN3                     1.0 gm 
PBS                   1000 mL 
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5. Preparation of NH4Cl Lysing Solution (5X) (1000 mL) 
Reagent                     Amount 
NH4Cl                       41.45 g 
KHCO3                         5.00 g 
EDTA-disodium salt                           0.185 g 
All the above reagents are transferred to 1L D/W, mixed, filtered by 0.2µl filter and then 
it is ready for use. Working conc. is 1X.  
6. Preparation of Gentamycin (10mg/mL) 
Reagent                    Amount 
ISCOVE media                       15 mL 
Gentamycin                     0.15 g 
 
 0.15g Gentamycin was measured and taken in ISCOVE media and final volume 
was made to 15mL in a beaker was filtered with 0.2um filter. 
 1mL gentamycin was aliquoted in each eppendorf and stored at -20C. 
 
7. Preparation of Mercaptoethanol 
 
Reagent Amount 
DMEM complete medium 50 mL 
Mercaptoethanol 17.5 µL 
 
 17.5uL ME was taken in 50mL DMEM complete medium. 
 Finally 1mL ME was aliquoted  in each eppendorf and stored at -20C. 
 
8. Preparation of Indicator Solution 
                                                              Sterile Saline    Bacteria    Complement 
V. cholerae O1 (X25049 & 19479)      2.55 ml               150 µl             300 µl 
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APPENDIX C 
 Preparation of Media 
1. Preparation of  DMEM complete medium  (50mL)  
Reagent                                     Amount 
DMEM media                                        44 mL 
Fetal Bovine Serum (10% FBS)                                          5 mL 
Gentamycin (1%)                                       0.5 mL 
Merchaptoethanol (1%)                                       0.5 mL 
 
2. Preparation of Iscove (1X) Medium (1000mL) 
 
3. Preparation of BHI medium (Brain Heart Infusion medium) (1000 ml) 
 
APPENDIX D 
  Software’s 
1. CELL QUEST PRO (version 3.3; Becton Dickinson) 
2. Flow Jo (Tree Star, Inc., version 8.5.3) 
3. Prism 5.0 (Graph PAD Software 10855 Sorrento Valley Road #203, San Diego, 
CA 92121 USA) 
4. Microsoft Word and Excell 
Reagent                                                                                                 Amount 
Iscove            17.77 gm 
Deionized Water              1000 ml 
Reagent                                                                                                Amount 
Bacto
TM
 Brain Heart Infusion                        37 gm 
Aotoclaved deionized Water                  1000 ml 
